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than 5 decades  [ 521 ,  522 ] , growing evidence sug-
gests that improving the way the available medi-
cations are administered may bring substantial 
benefi t to patients  [ 45 ] . Evidence-based guidelines 
for optimum treatment have been published dur-
ing the last decade  [ 23 ,  46 ,  101 ,  204 ,  205 ,  221 ,  234 , 
 254 ,  276 ,  284 ,  582 ,  585 ,748].
 A valuable tool for tailoring the dosage of the 
 prescribed medication(s) to the individual char-
acteristics of a patient is therapeutic drug moni-
toring (TDM). The major reason to use TDM for 
the guidance of psychopharmacotherapy is the 
 Introduction
 ▼
 In psychiatry, around 130 drugs are now availa-
ble which have been detected and developed 
during the last 60 years  [ 54 ] . These drugs are 
eﬀ ective and essential for the treatment of many 
psychiatric disorders and symptoms. Despite 
enormous medical and economic benefi ts, how-
ever, therapeutic outcomes are still far from 
satis factory for many patients  [ 5 ,  6 ,  396 ,  661 ] . 
Therefore, after having focused clinical research 
on the development of new drugs during more 
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 Abstract
 ▼
 Therapeutic drug monitoring (TDM), i. e., the 
quantifi cation of serum or plasma concentra-
tions of medications for dose optimization, has 
proven a valuable tool for the patient-matched 
psychopharmacotherapy. Uncertain drug adher-
ence, suboptimal tolerability, non-response at 
therapeutic doses, or pharmacokinetic drug-drug 
interactions are typical situations when meas-
urement of medication concentrations is help-
ful. Patient populations that may predominantly 
benefi t from TDM in psychiatry are children, 
pregnant women, elderly patients, individuals 
with intelligence disabilities, forensic patients, 
patients with known or suspected genetically 
determined pharmacokinetic abnormalities or 
individuals with pharmacokinetically relevant 
comorbidities. However, the potential benefi ts 
of TDM for optimization of pharmacotherapy 
can only be obtained if the method is adequately 
integrated into the clinical treatment process. To 
promote an appropriate use of TDM, the TDM 
expert group of the Arbeitsgemeinschaft für 
Neuropsychopharmakologie und Pharmakopsy-
chiatrie (AGNP) issued guidelines for TDM in 
psychiatry in 2004. Since then, knowledge has 
advanced signifi cantly, and new psychopharma-
cologic agents have been introduced that are also 
candidates for TDM. Therefore the TDM consen-
sus guidelines were updated and extended to 128 
neuropsychiatric drugs. 4 levels of recommenda-
tion for using TDM were defi ned ranging from 
“strongly recommended” to “potentially useful”. 
Evidence-based “therapeutic reference ranges” 
and “dose related reference ranges” were elabo-
rated after an extensive literature search and a 
structured internal review process. A “laboratory 
alert level” was introduced, i. e., a plasma level at 
or above which the laboratory should immedi-
ately inform the treating physician. Supportive 
information such as cytochrome P450 substrate- 
and inhibitor properties of medications, nor-
mal ranges of ratios of concentrations of drug 
metabolite to parent drug and recommendations 
for the interpretative services are given. Recom-
mendations when to combine TDM with phar-
macogenetic tests are also provided. Following 
the guidelines will help to improve the outcomes 
of psychopharmacotherapy of many patients 
especially in case of pharmacokinetic problems. 
Thereby, one should never forget that TDM is an 
interdisciplinary task that sometimes requires 
the respectful discussion of apparently discrep-
ant data so that, ultimately, the patient can profi t 
from such a joint eﬀ ort.
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considerable interindividual variability in the pharmacokinetic 
properties of the patient  [ 524 ,  526 ] . At the very same dose, a 
more than 20-fold interindividual variation in the medication’s 
steady state concentration in the body may result, as patients 
diﬀ er in their ability to absorb, distribute, metabolize and 
excrete drugs due to concurrent disease, age, concomitant medi-
cation or genetic peculiarities  [ 61 ,  94 ,  310 ,  311 ,  334 ,  335 ,  374 ] . 
Diﬀ erent formulations of the same medication may also infl u-
ence the degree and temporal pattern of absorption and, hence, 
medication concentrations in the body. TDM uses the quantifi -
cation of drug concentrations in blood plasma or serum to titrate 
the dose of individual patients so that a drug concentration 
associated with highest possible probability of response and 
 tolerability and a low risk of toxicity can be obtained. Moreover, 
TDM has the possible and widely unexploited potential to 
improve cost-eﬀ ectiveness of psychopharmacotherapy  [ 527 ,  660 ] . 
For a considerable number of psychopharmacologic compounds, 
the quantifi cation of the medications’ plasma concentration has 
become clinical routine for dose adjustment. Clear evidence of 
the benefi ts of TDM has been given for tricyclic antidepressants, 
a number of old and new antipsychotic drugs and for conven-
tional mood stabilizing drugs  [ 51 ,  459 ,  505 ] . For lithium, TDM 
has become a standard of care due to its narrow therapeutic 
range  [ 133 ,  395 ] .
 The benefi ts of TDM regarding the optimization of pharmaco-
therapy, however, can only be obtained if the method is ade-
quately integrated into the clinical treatment process. Current 
TDM use in psychiatric care is obviously suboptimal 
 [ 134 ,  700 ,  742 ] . Similar to other medical disciplines, systematic 
studies have demonstrated that the inappropiate use of TDM is 
widespread. Inappropriate TDM testing wastes laboratory 
resources and also bears the risk that misleading results will 
adversely infl uence clinical decision making  [ 122 ] . A study on 
the clinical use of TDM for tricyclic antidepressants in psychiat-
ric university hospital settings showed that between 25 and 40 % 
of the requests for TDM were inappropriate and the interpreta-
tion of the results led to about 20 % of inappropriate therapeutic 
adjustments  [ 700 ,  742 ] . Other typical errors were absence of 
steady-state conditions and transcription errors on the request 
form  [ 700,743 ] . Studies on TDM for antidepressant and mood 
stabilizing drugs further specifi ed the information on the inap-
propriate use of TDM  [ 420 ,  421 ] .
 Against this background, the TDM group of the Arbeitsgemein-
schaft für Neuropsychopharmakologie und Pharmakopsychi-
atrie (AGNP) issued best practice guidelines for TDM in 
psychiatry in 2004  [ 51 ] . These guidelines were widely accepted 
by many laboratories and practicing clinicians. They have been 
cited more than 200 times in the literature and were translated 
into German  [ 312 ] and French  [ 50 ] . Moreover, they were sum-
marized for depression  [ 52 ] . The AGNP-TDM consensus guide-
lines have also been implemented in recent international 
guidelines on the treatment of mental diseases  [ 582 ] . Since 
2004, knowledge on TDM has advanced signifi cantly. New psy-
chotropic medications have been introduced which are also can-
didates for TDM. The TDM group of the AGNP therefore decided 
to prepare an updated version of their guidelines.
 Objectives of this Consensus Document
 ▼
 This document addresses topics related to the theory and prac-
tice of TDM in psychiatry. The fi rst part deals with theoretical 
aspects of monitoring drug plasma concentrations. The second 
part defi nes indications for TDM and gives reference drug plasma 
concentrations for dose optimization. The third part describes 
the best practice of the process of TDM, which starts with the 
request and ends with the clinical decision to either continue or 
change the pre-TDM pharmacotherapy.
 Aiming to optimise the practice of TDM the following topics 
were addressed:
 ▶  defi nition of indications to utilize TDM in psychiatry 
 ▶  defi nition of graded levels of recommendations to use TDM 
 ▶  defi nition of therapeutic reference ranges (“therapeutic win-
dows”) and dose-related reference ranges that laboratories 
can quote and clinicians can use to guide the psychopharma-
cotherapy 
 ▶  defi nition of alert levels for laboratories to warn the treating 
physician when plasma concentrations are considered to be 
too high and potentially harmful 
 ▶  recommendations and help for interpretative services 
 ▶  recommendations concerning the combination of TDM with 
pharmacogenetic tests 
 Preparation of the Consensus Document
 ▼
 The updated consensus guidelines were prepared by the inter-
disciplinary TDM group of the AGNP consisting of clinical psy-
chiatrists, pharmacologists, biochemists, pharmacists and 
chemists from academic and non academic hospitals and insti-
tutions of Germany, Switzerland, Austria and Italy, who have 
been involved for many years in the development and imple-
mentation of TDM for psychotropic medications in everyday 
clinical practice. The experts compiled information from the lit-
erature and worked out the present best practice guidelines 
aiming at promoting the appropriate use of TDM in psychiatry. 
Because TDM is widely used in daily clinical practice for antide-
pressant, antipsychotic and mood stabilizing drugs, these 3 
pharmacologic classes are extensively represented in the present 
guidelines. Anxiolytic and hypnotic drugs, antidementia drugs, 
drugs for treatment of substance abuse related disorders and 
other psychotropic drugs are also candidates for TDM and are 
thus covered in the present guidelines. In special situations, the 
measurement of drug plasma concentrations can be helpful for 
any drug. Many patients are simultaneously treated for neuro-
logic and psychiatric disorders. Therefore, the updated guide-
lines also contain information on anticonvulsant and 
antiparkinson drugs which are also more or less well established 
candidates for TDM  [ 481 ,  499 ] and were thus extended from 65 
psychiatric drugs in 2004  [ 51 ] to 128 neuropsychiatric drugs at 
present.
 Data published in the AGNP consensus guidelines 2004  [ 51 ] and 
other guidelines and recommendations for TDM of primarily 
antidepressant and antipsychotic drugs  [ 317 ,  400 ,  488 – 490 , 
 504 ,  505 ] were initially used as the basis for this update. An 
extensive literature search was conducted, primarily in 
MEDLINE, to identify TDM-related information for the surveyed 
128 neuropsychiatric drugs. The search concentrated on reports 
on “optimum plasma concentrations”, “dose related drug plasma 
concentrations”, “cytochrome P450 substrate, inducer and 
inhibitor properties” and on “ratios of concentrations of drug 
metabolites to parent drugs”. Relevant reports were also 
searched by hand in pharmacologic and clinical chemical jour-
nals dealing with TDM. Over 1 000 articles were assessed and 
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analysed. Extracted data on reference ranges were listed in 
tables by 7 authors (CH, EH, CG, BR, PR, HK). Results of the litera-
ture search and analyses were sent out for review to 20 mem-
bers of the TDM group with inclusion of a checklist how to 
extract and analyse the data. An internet based and password-
protected platform was built up for the reviewers to have access 
to relevant articles. The reviewers’ protocols and commentaries 
were distributed to all authors of these guidelines. Final deci-
sions on data reported in this document were made during 2 
consensus conferences and by e-mail communication. Consen-
sus making also included defi nitions of reference ranges, alert 
levels and graded levels of recommendations to utilize TDM.
 Theoretical Aspects of TDM in Psychiatry
 ▼
 Pharmacokinetics, metabolism and pharmacogenetics 
of neuropsychiatric drugs
 Most psychotropic drugs share a number of pharmacokinetic 
characteristics
 ▶  good absorption from the gastrointestinal tract within plasma 
concentrations reaching a maximum within 1–6 h 
 ▶  highly variable fi rst-pass metabolism (systemic bioavaila-
bility ranging 5–90 %) 
 ▶  fast distribution from plasma to the central nervous system 
with 2- to 40-fold higher levels in brain than in blood 
 ▶  high apparent volume of distribution (about 10–50 L/kg) 
 ▶  low trough plasma concentrations under steady-state (about 
0.1–500 ng/mL for psychoactive drugs and up to 20 μg/mL for 
neurological drugs) 
 ▶  slow elimination from plasma (half-life 12–36 h) mainly by 
hepatic metabolism 
 ▶  linear pharmacokinetics at therapeutic doses which has the 
consequence that doubling the daily dose will result in a 
 doubling of the plasma level 
 ▶  low renal excretion with small eﬀ ect of renal insuﬃ  ciency on 
the plasma concentrations of parent drug and active meta bolites 
 ▶  cytochrome P450 (CYP) and UDP-glucuronosyltranferases as 
major metabolic enzyme systems 
 There are, however, numerous exceptions. For example, venla-
faxine, nefazodone, trazodone, tranylcypromine, moclobemide, 
quetiapine, rivastigmine and ziprasidone display short (about 
2–10 h) elimination half-lives, whereas aripiprazole and fl uoxetine 
have long elimination half-lives (72 h for aripiprazole and 3–15 
days for fl uoxetine, taking into account its active metabolite nor-
fl uoxetine). Amisulpride, milnacipran, memantine, gabapentin, or 
sulpiride are not or only poorly metabolised in the liver but also 
mainly excreted renally. Paroxetine exhibits non-linear pharma-
cokinetics, due to the inhibition of its own metabolism by a 
metabolite which is irreversibly bound to the enzyme (mechanism 
based inhibition) resulting in its inactivation  [ 69 ] .
 Many psychotropic drugs are used as racemic compounds, and 
their enantiomers diﬀ er markedly in their pharmacology, 
metabolism and pharmacokinetics  [ 53 ,  605 ] . So far however, 
methadone, methylphenidate and fl upentixol are at present the 
only racemic psychotropic compounds for which TDM of the 
enantiomers has been introduced  [ 39 ,  189 ] . The active princi-
ples of racemic methadone and fl uoxetine are (R)-methadone 
and cis-(Z)-fl upentixol, respectively. For research projects and 
other special situations, stereoselective analysis should be con-
sidered, e. g., for citalopram, fl uoxetine, reboxetine, venlafaxine, 
paliperidone or amitriptyline metabolites.
 Most psychotropic drugs undergo phase-I metabolism by oxida-
tive (e. g., hydroxylation, dealkylation, oxidation to N-oxides, 
S-oxidation to sulfoxides or sulfones), reductive (e. g., carbonyl 
reduction to secondary alcohols) or hydrolytic reactions, 
dealkylation, oxidation to N-oxides, carbonyl reduction to sec-
ondary alcohols or S-oxidation to sulfoxides or sulfones. The 
phase-I reactions are predominantly catalysed by cytochrome 
P450 (CYP) enzymes which comprise more than 200 isoen-
zymes. The most important isoenzymes for psychotropic medi-
cations are CYP1A2, CYP2B6, CYP2D6, CYP2C9, CYP2C19 and 
CYP3A4/5 (  ●  ▶   Table 1 )  [ 745 – 747 ] . In general, phase-I reactions 
introduce a polar functional group that enables a phase-II conju-
gation reaction with highly polar molecules such as glucuronic 
or sulphuric acid. For psychotropic compounds possessing func-
tional groups in the parent compound, glucuronidation of a 
hydroxyl group (for example oxazepam or lorazepam) or an N-H 
group (for example olanzapine) may represent the essential 
metabolic pathway. In addition, tertiary amine groups can be 
conjugated with the formation of quaternary ammonium glu-
curonides. Actually, phase II enzymes are poorly characterised 
with regard to substrate specifi city, and there is much overlap 
between the isozymes regarding aﬃ  nity for substrates  [ 143 ] .
 Other enzymatic systems may also be involved, such as keto-
aldehyde oxidases  [ 43 ] , which have been shown to reduce 
ziprasidone to its dihydro-derivative  [ 58 ] or naltrexone to nal-
trexol  [ 92 ] , or MAO-A and MAO-B, which deaminate citalopram 
stereoselectively to an apparently inactive acidic metabolite 
 [ 562 ] .
 Drugs are metabolised mainly in the liver and, to a minor degree, 
in extrahepatic tissues such as the intestinal mucosa or the brain 
 [ 59 ,  238 ,  444 ] . Inter- and intra-individual diﬀ erences in plasma 
concentrations of psychotropic drugs (i. e., the pharmacokinetic 
variability) are caused by diﬀ erent activities of drug-metabolis-
ing enzymes. The enzyme activity may decrease with age  [ 374 ] 
and can be modifi ed by renal and hepatic diseases. Gender dif-
ferences have been reported for psychotropic drugs, but the 
fi ndings are inconsistent and the clinical relevance is not clear 
 [ 7 – 9 ,  608 ] .
 For a number of psychoactive drugs, metabolites actively con-
tribute to the overall clinical eﬀ ect of the parent compound. For 
this reason, TDM must include the quantifi cation of active 
metabolites, e. g., in the case of clomipramine (norclomi-
pramine), doxepin (nordoxepin), fl uoxetine (norfl uoxetine) or 
risperidone (9-hydroxyrisperidone). For drugs like sertraline or 
clozapine, the clinical relevance of their metabolites norsertra-
line and norclozapine, respectively, is still a matter of debate. 
The analysis of pharmacologically inactive metabolites, how-
ever, may give useful information on the metabolic state of the 
patient or on his/her compliance  [ 105 ,  569 ] .   ●  ▶   Table 2 shows the 
“normal” ratios of concentrations of metabolites to parent drugs. 
Calculated ranges contain 68 % of the ratios expected under 
standard dosages, i. e., ratios within the range of the mean ± 1 SD 
assuming normal distribution. A ratio above or below the “nor-
mal ratio” (  ●  ▶   Table 2 ) can indicate problems of drug adherence 
 [ 546 ] or metabolic abnormalities due to a genetic variation 
 [ 157 ,  159 ,  350 ,  592 ] or a drug-drug interaction. Spina and co -
workers  [ 618 ] have shown this for the conversion of 2-hydroxy-
desipramine to desipramine. With regard to drug-drug interactions, 
ratios increase if the enzymatic conversion of the parent medi-
cation is induced by concurrent psychotropic or non-psycho-
tropic medications or pharmacokinetically relevant activities 
such as smoking (  ●  ▶   Table 3 ). Other co-medications and food 
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 Table 1  Psychopharmacologic medications and enzymes involved in their metabolism.  
 Drug (active metabolite)  Enzymes  Reference 
 Acamprosate  not involved (not metabolized)  [ 578 ] 
 Agomelatine  CYP1A2 , CYP2C19  [ 78 ] 
 Amantadine  merely involved (90 % excreted unmetabolized)  [ 24 ] 
 Alprazolam  CYP3A4/5  [ 17 ,  496 ] 
 Amisulpride  merely involved (more than 90 % is excreted 
unmetabolized via the kidney) 
 [ 566 ] 
 Amitriptyline and amitriptyline oxide (amitriptyline, nortriptyline)  CYP1A2, CYP2C9,  CYP2C19, CYP2D6 , CYP3A4  [ 90 ,  650 ,  713 ] 
 Aripiprazole (dehydroaripiprazole)  CYP2D6, CYP3A4  [ 306 ,  701 ] 
 Asenapine  Glucuronosyltransferase and CYP1A2  [ 707 ] 
 Atomoxetine  CYP2D6  [ 446 ] 
 Benperidol  unclear  [ 589 ] 
 Benserazide  hydroxylation, COMT  [ 347 ] 
 Biperiden  hydroxylation  [ 628 ] 
 Bromocriptine  CYP3A4  [ 513 ] 
 Bromperidol  CYP3A4  [ 230 ,  633 ,  645 ,  736 ] 
 Brotizolam  CYP3A4  [ 655 ] 
 Buprenorphine (norbuprenorphine)  CYP2C8,  CYP3A4  [ 79 ,  454 ] 
 Bupropion (hydroxybupropion)  CYP2B6  [ 309 ] 
 Buspirone  CYP3A4  [ 416 ] 
 Cabergoline  hydrolysis, CYP3A4  [ 167 ] 
 Carbidopa  unknown metabolic pathways 1/3 unmetabolized  [ 575 ] 
 Carbamazepine, CBZ (CBZ-10,11-epoxide)*  CYP1A2, CYP2B6, CYP2C8,  CYP3A4/5  [ 360 ,  497 ] 
 Chlorpromazine  CYP1A2, CYP2D6  [ 724 ] 
 Citalopram  CYP2C19, CYP2D6, CYP3A4  [ 97 ,  227 ,  739 ] 
 Clomipramine (norclomipramine)  CYP1A2,  CYP2C19, CYP2D6, CYP3A4  [ 244 ] 
 Clomethiazol  CYP2A6, CYP2B6, CYP3A4  [ 116 ] 
 Clozapine  CYP1A2, CYP2C19, CYP3A4  [ 334 ,  487 ] 
 Desipramine  CYP2D6  [ 244 ] 
 Diazepam (nordazepam, oxazepam, temazepam)  CYP2B6,  CYP2C19, CYP3A4  [ 228 ,  704 ] 
 Dihydroergocryptine  CYP3A4  [ 19 ,  162 ] 
 Diphenhydramine  CYP2D6  [ 13 ] 
 Disulfi ram  CYP1A2, CYP2B6, CYP2E1, CYP3A4  [ 412 ] 
 Donepezil  CYP2D6, CYP3A4  [ 681 ] 
 Dothiepin = Dosulepin  CYP2C19, CYP2D6  [ 740 ] 
 Doxepin (nordoxepin)  CYP2C9, CYP2C19, CYP2D6  [ 295 ,  365 ] 
 Duloxetine  CYP1A2, CYP2D6  [ 405 ] 
 Entacapone  Glucuronosyltransferase  [ 387 ] 
 Escitalopram  CYP2C19, CYP2D6, CYP3A4  [ 662 ,  697 ] 
 Fluoxetine (norfl uoxetine)  CYP2B6,  CYP2C9, CYP2C19, CYP2D6  [ 404 ,  588 ] 
 Flupenthixol  CYP2D6  [ 148 ,  365 ] 
 Fluphenazine  CYP2D6  [ 746 ] 
 Fluvoxamine  CYP2D6, CYP1A2  [ 354 ,  450 ] 
 Galantamine  CYP2D6, CYP3A4  [ 34 ] 
 Gabapentin  unmetabolized renal excretion  [ 77 ] 
 Haloperidol  CYP2D6,  CYP3A4  [ 93 ,  645 ] 
 Iloperidone  CYP2D6, CYP3A4  [ 106 ] 
 Imipramine (desipramine)  CYP1A2, CYP2C19, CYP2D6, CYP3A4  [ 244 ,  413 ] 
 Lamotrigine  Glucuronosyltransferase, CYP2A6  [ 121 ] 
 Levodopa  Dopadecarboxylase, COMT, MAO  [ 575 ] 
 Levomepromazine  CYP1A2, CYP2D6  [ 36 ] 
 Levomethadon  CYPC19, CYP2B6,  CYP3A4, CYP2D6  [ 145 ] 
 Lisuride  CYP3A4, CYP2D6  [ 539 ] 
 Lithium  no metabolism, renal clearance  [ 256 ,  619 ] 
 Lorazepam  Glucuronosyltransferase  [ 164 ,  196 ] 
 Maprotiline  CYP2D6 , CYP1A2  [ 86 ] 
 Melatonin  CYP1A2  [ 296 ] 
 Memantine  merely metabolized  [ 251 ] 
 Methadone  CYP2B6, CYP2C19, CYP3A4, CYP2D6  [ 145 ] 
 Methylphenidate  Carboxylesterase 1  [ 468 ] 
 Mianserine  CYP2D6, CYP1A2, CYP3A4  [ 379 ] 
 Midazolam  CYP3A4  [ 220 ] 
 Milnacipran  no CYP related metabolism  [ 495 ,  533 ] 
 Inhibition of enzymes indicated in bold will signifi cantly increase the plasma concentrations of the drug, induction (CYP1A2, CYP3A4) will lead to decreased plasma concentra-
tions (See   ●  ▶   Table 2 ). Prepared by CH, reviewed and supplemented by EJS 
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which inhibit metabolic enzymes may decrease the ratio.   ●  ▶   Table  3 
summarizes drugs that are inhibitors or inducers of CYP enzymes 
and thus may lead to clinically relevant pharmacokinetic drug-
drug interactions.
 Pharmacogenetic aspects
 The clinical importance of pharmacogenetic factors in the phar-
macokinetics and pharmacodynamics of psychoptropic drugs is 
increasingly recognised  [ 156 ,  199 ,  457 ] . Drug-metabolising 
enzymes, especially CYP isoenzymes, exhibit genetic variability 
 [ 745 – 747 ] . When the frequency of a deviation in the alleles is at 
least 1 % of the population, it is considered a genetic polymor-
phism. The number of active alleles in a gene determines how 
much of the enzyme is expressed (phenotype). Poor metabolis-
ers (PM) lack functional alleles. Intermediate metabolisers (IM) 
are either genetically heterozygous, carrying an active and an 
inactive allele (or an allele with reduced activity) or have 2 alle-
les with reduced activity. Extensive metabolisers (EM) are wild-
type with 2 active alleles, and ultra-rapid metabolisers (UM) 
have an amplifi cation of functional alleles  [ 66 ] . Genetic poly-
morphisms of drug-metabolising enzymes may be clinically 
important, because unexpected adverse reactions and toxicity 
may occur in PM due to increased plasma concentrations and 
non-response may occur in UM due to subtherapeutic plasma 
concentrations  [ 160 ] . Prodrugs are activated by metabolism 
such as codeine by CYP2D6 to morphine or clopidogrel by 
CYP2C19 to 2-oxoclopidogrel. PM patients will not be able to 
produce pharmacologically active metabolites. Other enzyme 
systems such as UDP-glucuronosyltransferases also display 
genetic polymorphism  [ 155 ] , but their clinical relevance in 
pharmacopsychiatry is unclear.
 CYP genotyping methods are becoming more and more availa-
ble, and guidelines have been published for their use in clinical 
practice  [ 675 ] . The functional signifi cance of many genotypes, 
 Table 1  Psychopharmacologic medications and enzymes involved in their metabolism.  
 Drug (active metabolite)  Enzymes  Reference 
 Mirtazapine  CYP3A4, CYP1A2, CYP2B6, CYP2D6  [ 397 ,  630 ] 
 Moclobemide  CYP2C19, CYP2D6  [ 255 ] 
 Modafi nil  Amide hydrolysis, CYP3A4  [ 561 ] 
 Naltrexone  Aldoketoreductase AKR1C4  [ 92 ] 
 Nortriptyline  CYP2D6  [ 385 ,  485 ,  687 ] 
 Olanzapine  N-Glucuronosyltransferase, Flavin monoxigenase, 
 CYP1A2 , CYP2D6 
 [ 107 ] 
 Opipramol  unclear  
 Paliperidone ( = 9-Hydroxyrisperidone)  60 % excreted unmetabolized, diﬀ erent pathways  [ 161 ] 
 Paroxetine  CYP1A2,  CYP2D6 , CYP3A4  [ 209 ,  349 ,  691 ] 
 Perazine  CYP1A2,  CYP2C19 , CYP3A4, Flavin monoxigenase  [ 629,725 ] 
 Pergolide  CYP3A4  [ 731 ] 
 Perphenazine  CYP1A2, CYP2C19,  CYP2D6, CYP3A4  [ 12 ,  77 ,  168 ,  486 ] 
 Pregabalin  unmetabolized renal excretion  [ 77 ] 
 Piripedil  demethylation, p-hydroxylation, and N-oxidation  [ 168 ] 
 Pimozide  CYP1A2,  CYP3A4  [ 171 ] 
 Pramipexole  not metabolized  [ 62 ] 
 Promazine  CYP1A2, CYP2C19, CYP3A4  [ 726 ] 
 Promethazine  CYP2D6  [ 465 ] 
 Quetiapine  CYP3A4, CYP2D6   [ 38 ] 
 Rasagiline  CYP1A2  [ 277 ] 
 Reboxetine  CYP3A4  [ 307 ,  716 ] 
 Risperidone (9-Hydroxyrisperidone)  CYP2D6, CYP3A4  [ 732 ] 
 Ropinirole  CYP1A2  [ 357 ] 
 Rotigotine  Glucuronosyltransferase, several other unknown pathways  [ 115 ] 
 Selegiline  CYP2B6  [ 60 ] 
 Sertindole  CYP3A4, CYP2D6  [ 729 ] 
 Sertraline  CYP2B6, CYP2C19, CYP2C9, CYP2D6  [ 482 ,  705 ] 
 Thioridazine  CYP1A2, CYP2C19,  CYP2D6, CYP3A4  [ 648 ,  714 ] 
 Tiapride  mainly not metabolized  [ 477 ] 
 Tolcapone  Glucuronosyltransferase  [ 387 ] 
 Trimipramine (nortrimipramine)  CYP2C19, CYP2D6, CYP2C9  [ 187 ] 
 Tranylcypromine  monoamine oxidase, unclear  [ 37 ] 
 Trazodone  CYP3A4, CYP2D6  [ 268 ,  567 ] 
 Valproic acid  Glucuronosyltransferase, CYP2A6, CYP2B6, CYP2C9, 
 beta-oxidation 
 [ 641 ] 
 Venlafaxine (O-desmethylvenlafaxine)  CYP2C19,  CYP2D6, CYP3A4  [ 217 ,  434 ] 
 Zaleplone  Aldehyde oxidase, CYP3A4  [ 554 ] 
 Ziprasidone  CYP3A4, Aldehyde oxidase  [ 58 ,  519 ] 
 Zolpidem  CYP1A2, CYP2C9,  CYP3A4  [ 698 ] 
 Zopiclone  CYP2C8,  CYP3A4  [ 57 ,  659 ] 
 Zotepine  CYP1A2, CYP2D6,  CYP3A4  [ 596 ] 
 Zuclopenthixol  CYP2D6  [ 330 ] 
 Inhibition of enzymes indicated in bold will signifi cantly increase the plasma concentrations of the drug, induction (CYP1A2, CYP3A4) will lead to decreased plasma concentra-
tions (See   ●  ▶   Table 2 ). Prepared by CH, reviewed and supplemented by EJS 
Continued.
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however, is unclear. For some enzymes, a genetic polymorphism 
is not clearly demonstrated despite the fact that they display a 
wide interindividual variability in their activity. Therefore it 
may be advantageous to use phenotyping methods with probe 
drugs such as caﬀ eine for CYP1A2, omeprazole for CYP2C19, 
dextromethorphan for CYP2D6, or midazolam for CYP3A4/5 
 [ 403 ,  643 ] . Phenotyping measures the metabolic situation of the 
patient at the moment of the test, and allows to follow its evolu-
tion. The measurement, however, may be infl uenced by environ-
mental factors such as smoking or comedications  [ 201 ,  601 ,  749]. 
The clear advantage of genotyping is that it represents a “trait 
marker” and that its result is not infl uenced by environmental 
factors. It can be carried out in any situation and its result has a 
lifetime value.
 Table 2  Ranges of metabolite-to-parent concentration ratios for psychopharmacologic medications. Reported ranges contain 68 % of ratios determined under 
“normal” conditions in the blood of patients or healthy subjects. 
 Drug  Metabolite  Ratios of concentrations metabolite: 
parent drug (Mean ̶  SD – Mean + SD) 
 Reference 
 Amitriptyline  Nortriptyline*  0.2–1.8 (n = 83)  [ 545 ] 
 Aripiprazole  Dehydroaripirazole(*)  0.3–0.5 
 PM of CYP2D6: 0.2 
 [ 306 ,  368 ,  452 ] 
 Bromperidol  Reduced bromperidol  0.11–0.51 (n = 31)  [ 609 ,  633 ] 
 Buprenorphine  Norbuprenorphine  0.8–2.0 (n = 5)  [ 383 ] 
 Bupropion  Hydroxybupropion  5–47 (24 h, n = 9) 
 6–30 (12 h, n = 9) 
 [ 152 ,  253 ,  336 ] 
 Buspirone  6-Hydroxybuspirone  25–53 (n = 20)  [ 178 ] 
 Carbamazepine  Carbamazepine-10,11-epoxide  0.07–0.25 (n = 14)  [ 338 ] 
 Citalopram  N-Desmethylcitalopram  0.31–0.60 (n = 2 330)  [ 549 ] 
 Clomipramine  Norclomipramine*  0.8–2.6 (n = 115)  [ 545 ] 
 Clozapine  Norclozapine(*)  nonsmokers (n = 98) 
 0.5–0.6 
smokers (n = 198) 
 0.4–0.7 
 [ 140 ,  308 ,  500 ] 
 Dothiepin  Nordothiepin  0–1.4 (n = 50)  [ 325 ] 
 Doxepin  Nordoxepin  0.6–1.6 (n = 12) 
 PM CYP2C19: 1.8 (n = 4) 
 PM CYP2D6: 0.8 (n = 6) 
 [ 172 ,  363 ] 
 Escitalopram  N-Demethylescitalopram  0.3–1.0 (n = 243)  [ 548 ] 
 Fluoxetine  Norfl uoxetine*  0.7–1.9 (n = 334)  [ 545 ] 
 Fluvoxamine  Fluvoxamino acid  0–1.2 (n = 49)  [ 237 ] 
 Haloperidol  Reduced haloperidol  mean 0.6  [ 673 ] 
 Imipramine  Desipramine  0.6–3.2 (n = 14) 
 PM CYP2D6 4.1 (n = 2) 
 [ 95 ,  96 ,  632 ] 
 Maprotiline  Desmethylmaprotiline  1.1–3.7 (n = 76) 
 PM CYP2D6 4.9 
 [ 699 ] 
 Mianserin  N-Desmethylmianserin  0.5–0.8 (n = 182)  [ 545 ] 
 Mirtazapine  N-Desmethylmirtazapine  0.2–1.2 (n = 100)  [ 591 ] 
 Moclobemide  Moclobemide N-oxide  0.8–2.5 (n = 6)  [ 291 ] 
 Olanzapine  N-Demethylolanzapine  non smokers: 0.1–0.3 
 (n = 76) 
 smokers: 0.2–0.4 
 (n = 69) 
 [ 602 ] 
 Perazine  Desmethylperazine  1.1–3.3 (n = 27)  [ 91 ] 
 Perphenazine  N-Dealkylperphenazine  0.6–2.8 (n = 54)  [ 637 ] 
 Quetiapine  Norquetiapine  0.1–3.8 (n = 25) 
 (calculated for 400 mg) 
 [ 723 ] 
 Reboxetine  O-Desethylreboxetine  < 0.1  [ 484 ] 
 Risperidone  9-Hydroxyrisperidone*  EM or IM CYP2D6: 1.5–10.0 
 PM CYP2D6: ≤ 1 
 [ 159 ,  677 ] 
 Risperidone depot  9-Hydroxyrisperidone*  EM: 1.2–4.3  [ 469 ] 
 Sertindole  Dehydrosertindole  1.1–2.7 (n = 6) 
 1.0 in PM of CYP2D6 
 [ 729 ] 
 Sertraline  Norsertraline  1.7–3.4 (n = 348)  [ 546 ] 
 Trazodone  m-Chlorophenylpiperazine (mCPP)  0.04–0.22 (total range)  [ 328 ] 
 Trimipramine  Nortrimipramine*  0–12.0 (n = 17)  [ 142 ] 
 Venlafaxine  O-Desmethylvenlafaxine* 
 N-Desmethylvenlafaxine 
 EM or IM CYPD26: 0.3–5.2 
 PM CYP2D6: ≤ 0.3 
 UM CYP2D6: > 5.2 
 0.46–1.48 
 [ 592 ] 
 *pharmacologically active metabolite, (*) active metabolite in vitro but unclear under in vivo conditions 
 When SD values of ranges of ratios (SD ratio) were not reported in the literature, SD ratios were calculated in accordance with Gaussian’s law for the propagation of errors: SD 
ratio = [(SD parent drug x mean metabolite)+(SD metabolite x mean parent drug)]/(mean metabolite) 2 
 Prepared by CH, reviewed by Sonja Brünen, Christiane Knoth, Elnaz Ostad Haji and Viktoria Stieﬀ enhofer 
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 Recent investigations indicate that the drug eﬄ  ux transporter 
P-glycoprotein (P-gp) in the intestinal mucosa and blood-brain-
barrier is also relevant for the pharmacokinetic variability of 
psychotropic medications  [ 1 ] . This protein, a member of the 
ATP-cassette binding (ABC) transporter protein family, is 
encoded by the multidrug resistance gene ( MDR1 ;  ABCB1 ). It dis-
plays a genetic polymorphism, but as yet, mainly genotyping but 
not phenotyping (e. g., with digoxin) is more commonly used 
 [ 129 ,  183 ,  210 ,  389 ] . Genetic polymorphism of P-gp may be of 
the same considerable clinical relevance as has been demon-
strated for drug-metabolizing enzymes. For antidepressant 
drugs that are substrates of P-gp, a genotype dependent associa-
tion of drug response was found  [ 668 ,  669 ] . Both plasma concen-
trations of quetiapine and its clinical eﬀ ectiveness have been 
shown to depend on the P-gp genotype of patients suﬀ ering 
from schizophrenia  [ 470 ] . With regard to the occurrence of 
wanted or unwanted clinical eﬀ ects of psychoactive drugs, some 
fi rst reports suggest the infl uence of the genetic polymorphism 
of P-gp  [ 279 ,  560 ] . However, further research is needed to evalu-
ate the clinical relevance of the genetic polymorphisms of drug 
transporters.
 Dose and drug concentration in blood
 In most situations that use TDM for dose optimization, drugs are 
administered in a series of repeated doses to attain a steady-
state concentration within a given therapeutic reference range. 
Steady-state is attained when the rate of medication input 
equals the rate of medication loss, i. e., approximately after 4 
times the elimination half life. With multiple dosing, 94% of the 
steady state are achieved after 4 and 97% after 5 elimination 
half-lives. For more than 90 % of all psychoactive medications, 
such a steady-state is reached within 1 week of maintenance 
 Table 3  Inhibitors and inducers of enzymes involved in the metabolism of drug. 
 Inhibiting drugs  Inhibited enzymes  Inducing drugs  Induced enzymes 
 Amiodarone  CYP2C9, CYP2D6, CYP3A4  Carbamazepine  CYP1A2, CYP2B6, CYP2C9, CYP3A4 
 Bupropion  CYP2D6  Dexamethason  CYP2C9, CYP3A4 
 Bromocriptine  CYP3A4  Efavirenz  CYP2B6, CYP3A4 
 Chinidine  CYP2D6  Ethanol  CYP2E1 
 Cimetidin  CYP1A2, CYP2D6, CYP3A4  Ginkgo biloba  CYP2C19 
 Ciprofl oxacin  CYP1A2  Isoniazide  CYP2E1 
 Clarithromycin  CYP3A4  St. John’s wort  CYP2C19, CYP3A4 
 Clopidogrel  CYP2B6  Oxybutynin  CYP3A4 
 Disulfi ram  CYP2E1  Phenobarbital  CYP2C9, CYP2C19, CYP3A4 
 Duloxetine  CYP2D6  Phenytoin  CYP2B6, CYP2C9, CYP2C19, CYP3A4 
 Enoxacin  CYP1A2  Primidon  CYP2C9, CYP2C19, CYP3A4 
 Erythromycin  CYP3A4  Smoke  CYP1A2 
 Esomeprazole  CYP2C19  Rifabutin  CYP3A4 
 Felbamate  CYP2C19  Rifampicin  CYP1A2, CYP2B6, CYP2C9, CYP2C19 
 Fluconazole  CYP2C19, CYP2C9, CYP3A4  Ritonavir  CYP3A4, CYP2C9, CYP3A4 (high dose) 
 Fluoxetine and norfl uoxetine  CYP2D6, CYP2C19   
 Fluvoxamine  CYP1A2, CYP2C9, CYP2C19, CYP3A4   
 Indinavir  CYP3A4   
 Isoniazid  CYP1A2, CYP2A6, CYP2C19, CYP3A4   
 Itraconazol  CYP2B6, CYP3A4   
 Ketoconazol  CYP3A4   
 Levomepromazine  CYP2D6   
 Melperone  CYP2D6   
 Metoclopramide  CYP2D6   
 Metoprolol  CYP2D6   
 Miconazol  CYP2C9, CYP2C19   
 Mifepriston  CYP3A4   
 Moclobemide  CYP2C19, CYP2D6   
 Nelfi navir  CYP3A4   
 Norfl oxacine  CYP1A2   
 Omeprazole  CYP2C19   
 Paroxetine  CYP2D6   
 Perazine  CYP1A2   
 Pergolide  CYP2D6   
 Perphenazin  CYP2D6   
 Propafenon  CYP1A2, CYP2D6   
 Propranolol  CYP2D6   
 Ritonavir  CYP2D6, CYP3A4   
 Saquinavir  CYP3A4, CYP2C9   
 Troleandomycin  CYP3A4   
 Valproate  CYP2C9   
 Verapamil  CYP3A4   
 Voriconazol  CYP2C9, CYP3A4   
 Combination of psychoactive drugs with these inhibitors or inducers can lead to clinically relevant drug-drug interactions ( www.mediq.ch or www.psiac.de ) 
 Prepared by CH, reviewed by EJS 
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 Table 4  Total clearance (Cl t ), bioavailability (F), dosing intervals (τ) and factors (C/D low and C/D high ) for calculation of dose-related plasma concentrations (C/D) 
for psychotropic drugs. 
 Drug  n  Cl t ̶  SD – Cl t + SD 
[mL/min] 
 F  τ [h]  C/D low 
[ng/mL/mg] 
 C/D high 
[ng/mL/mg] 
 Reference 
 Antidepressant drugs 
 Amitriptyline  8  198–373  0.5  24  1.03  1.68  [ 165 ] 
 Amitriptyline oxide  12  331–539  0.8  24  0.93  1.75  [ 384 ] 
 Bupropion  17  2 500–11 300  1.0  24  0.06  0.28  [ 665 ] 
 Citalopram  8  367–545  0.8  24  1.02  1.51  [ 616 ] 
 Clomipramine  9  583–933  0.5  24  0.37  0.60  [ 198 ] 
 Desipramine  12  1 633–2 333  0.5  24  0.15  0.21  [ 2 ] 
 Desvenlafaxine  7  233–396  1.0  24  1.75  2.98  [ 520 ] 
 Dothiepin = Dosulepin  22  674–3 960  0.3  24  0.05  0.31  [ 740 ] 
 Doxepin  85  769–2 644  1.0  24  0.18  0.27  [ 100 ] 
 Duloxetine  12  610–1 733  0.5  24  0.20  0.57  [ 600 ] 
 Escitalopram  24  360–960  0.8  24  0.58  1.54  [ 607 ] 
 Fluoxetine  n. r.  600–833  0.7  24  0.60  0.83  [ 18 ] 
 Fluvoxamine  6  807–1 960  1.0  24  0.35  0.86  [ 163 ] 
 Imipramine  n. r.  791–1 029  0.4  24  0.28  0.37  [ 100 ] 
 Maprotiline  6  503–1 747  0.8  24  0.32  1.10  [ 415 ] 
 Mianserin  n. r.  843–1 948  0.3  24  0.11  0.25  [ 137 ] 
 Mirtazapine  10  455–945  0.5  24  0.37  0.85  [ 651 ] 
 Nordoxepin  85  504–2 738  1.0  24  0.25  1.38  [ 445 ] 
 Nortriptyline  n. r.  300–1 117  0.5  24  0.31  1.16  [ 664 ] 
 Paroxetine  30  1 561–10 856  1.0  24  0.06  0.44  [ 213 ] 
 Reboxetine  n. r.  22–51  1.0  24  12.55  31.10  [ 141 ] 
 Sertraline  11 (m) 
 11 (f) 
 1 313–2 213 (m) 
 793–2 357 (f) 
 1.0 
 1.0 
 24 
 24 
 0.31 
 0.29 
 0.53 
 0.88 
 [ 565 ] 
 Trazodone  8  73–103  1.0  24  6.72  9.47  [ 473 ] 
 Trimipramine  12  898–1 215  0.40  24  0.23  0.31  [ 165 ,  364 ] 
 Venlafaxine 
 O-Desmethylvenlafaxine 
 18  747–1 540 
 315–618 
 1.0 
 1.0 
 24 
 24 
 0.45 
 1.12 
 0.93 
 2.2 
 [ 372 ] 
 Antipsychotic drugs 
 Amisulpride  78  520–693  0.5  24  0.50  0.67  [ 566 ] 
 Asenapine  n. r.  867  0.35  24  0.28   [ 707 ] 
 Aripiprazole  6  47–70  0.9  24  8.63  12.85  [ 417 ] 
 Benperidol  14  1 073–2 240  0.5  24  0.15  0.31  [ 589 ] 
 Bromperidol  14  3 570–7 938  1.0  24  0.09  0.19  [ 390 ] 
 Chlorpromazine  11  1 043–1 510  0.1  24  0.05  0.07  [ 738 ] 
 Chlorprothixene  3  918–1 448  0.2  24  0.10  0.15  [ 534 ] 
 Clozapine  16  258–728  0.5  24  0.40  0.80  [ 128 ,  176 ,  332 ] 
 Flupentixol  3  440–490  0.6  24  0.78  0.87  [ 348 ] 
 Fluphenazine decanoate  12  2 380–3 940  1.0  24  0.18  0.29  [ 197 ] 
 Haloperidol  6  420–680  0.6  24  0.61  0.99  [ 123 ] 
 Haloperidol decanoate   420–680  1.0  336 
 672 
 0.073 
 0.036 
 0.118 
 0.059 
 [ 123 ] 
 Melperone  6  1 484–2 898  0.6  24  0.14  0.28  [ 83 ] 
 Levomepromazine  8  913–4 737  0.5  24  0.07  0.38  [ 149 ] 
 Olanzapine  491  233–637  0.8  24  0.87  2.38  [ 67 ] 
 Paliperidone  n. r.  31–98  0.3  24  1.99  6.31  [ 161 ] 
 Perphenazine  8  1 009–2 566  0.4  24  0.11  0.28  [ 195 ] 
 Pimozide  7  21–553  0.5  24  0.64  16.53  [ 581 ] 
 Quetiapine  10  1 146–2 421  1.0  24  0.13  0.21  [ 7 ,  435 ] 
 Risperidone, oral  8  91–171  0.7  24  3.50 
 active moiety 
 14.00 
 active moiety 
 [ 159 ] 
 Risperidone, depot  n. r.  91–171  1.0  336  0.29 
active moiety 
 0.55 
active moiety 
 [ 606 ] 
 Sertindole  6  133–600  1.0  24  1.16  5.22  [ 728 ] 
 Supiride  6  331–499  0.25  24  0.35  0.52  [ 717 ] 
 Thiordazine  11  404–982  0.60  24  0.42  1.03  [ 117 ] 
 Zotepine  14  467–10267  1.0  24  0.07  1.49  [ 642 ] 
 Ziprasidone  12  303–397  0.6  24  1.05  1.36  SPC 
 Zuclopenthixol  8  867–2 300  0.4  24  0.13  0.35  [ 337 ] 
 SPC: Summary of product characteristics; n.r.: not reported; active moiety: risperidone plus 9-hydroxyrisperidone; n: number of individuals; SD: standard deviation 
 Dose related ranges are obtained by multiplying C/D low and C/D high by the dose. Drugs listed in   ●  ▶   Table 5 were not included in this table, when clearance data were not 
 available from the literature. 
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dosing. The dose required to attain a steady-state concentration 
of a drug in plasma can be calculated if the dosing interval (τ), 
the clearance (Cl) and the bioavailability (F) for the drug in a 
particular patient are known. The calculation is based on the 
direct correlation of the drug dose D e  (constant dose per day at 
steady-state) to its blood concentration c, with the total clear-
ance of the drug (Cl t ) being the correlation coeﬃ  cient:
 D e  = DxF/τ = c x Cl t 
 Based on this information it is possible to calculate the dose-related 
plasma concentration of a drug that may be expected in blood 
specimens of patients under medication with a given dose  [ 285 ] :
 c = D e /Cl t 
 For psychoactive medications, such data are available from stud-
ies in which drug concentrations were measured in plasma of 
healthy volunteers or patients treated with fi xed doses. When 
the clearance is taken as arithmetic mean ± standard deviation 
from clinical trials of the drug, a dose related reference range can 
be calculated  [ 285 ] .
  ●  ▶   Table 4 lists factors for calculation of dose-related reference 
ranges for the most relevant psychoactive drugs. Dose-related 
reference ranges are calculated by multiplying C/D low and C/D high 
 Defi nition 
 The  “dose-related reference range” reported in the present 
guidelines is calculated as a concentration range within that a 
drug concentration is expected according to pharmacokinetic 
studies in human blood specimens from subjects under 
medi cation with a given dose of the drug. It contains 68 % of 
all the drug concentrations determined under normal condi-
tions in the blood of a “normal” patient or subject, “normal” 
being defi ned by the population in the respective clinical 
trial. It usually consists of individuals 18-65 years of age 
without relevant comorbidity, comedication, and genetic 
abnormalities in drug metabolism. 
 Table 4  Total clearance (Cl t ), bioavailability (F), dosing intervals (τ) and factors (C/D low and C/D high ) for calculation of dose-related plasma concentrations (C/D) 
for psychotropic drugs. 
 Drug  n  Cl t ̶  SD – Cl t + SD 
[mL/min] 
 F  τ [h]  C/D low 
[ng/mL/mg] 
 C/D high 
[ng/mL/mg] 
 Reference 
 Anticonvulsant drugs Mood stabilizers 
 Carbamazepine  n. r.  58–74  1.0  24  9.40  11.93  SPC 
 Felbamate  10  29.1–33.3  1.0  24  20.85  23.86  [ 556 ] 
 Lamotrigine  129  22–49  1.0  24  14.09  31.28  [ 118 ] 
 Levetiracetam  216  52–72  1.0  24  9.65  13.35  [ 535 ] 
 Lithium  n. r.  10–40  1.0  24  17.36  69.44  [ 706 ] 
 Oxcarbazepine  7  1 703–5 063  1.0  24  0.14  0.41  [ 319 ,  694 ] 
 Primidone  8  30–47  1.0  24  14.78  23.15  [ 423 ] 
 Topiramate  6  21–31  1.0  24  22.47  33.55  [ 179 ] 
 Valproic acid  9  4.5–9.8  1.0  24  71.23  154.32  [ 682 ] 
 Anxiolytic and hypnotic drugs 
 Alprazolam  6  34–83  0.8  24  6.73  16.53  [ 496 ,  604 ] 
 Bromazepam  10  50–91  1.0  24  7.67  13.95  [ 352 ] 
 Brotizolam  8  85–141  0.7  24  4.93  8.17  [ 341 ] 
 Buspirone  41  1 260–2 702  0.04  24  0.01  0.02  [ 41 ] 
 Clonazepam  9  63–90  0.8  24  5.43  7.69  [ 259 ] 
 Diazepam  48  10–43  0.9  24  13.01  52.91  [ 264 ] 
 Lorazepam  15  36–109  0.8  24  5.98  17.93  [ 266 ] 
 Oxazepam  18 (m) 
 20 (w) 
 36–167 
 29–109 
 0.8 
 0.8 
 24 
 24 
 3.33 
 5.12 
 15.22 
 18.90 
 [ 260 ] 
 Triazolam  13  326–584  0.9  24  1.01  1.81  [ 263 ] 
 Zaleplon  10  868–1 330  0.3  24  0.16  0.25  [ 265 ] 
 Zolpidem  10  266–364  0.67  24  1.02  2.14  [ 265 ] 
 Zopiclone  10  250–883  1  24  0.79  2.78  [ 411 ] 
 Antidementia drugs 
 Donepezil  14  112–217  1.0  24  3.20  6.20  [ 463 ] 
 Galantamine  8  268–400  1.0  24  1.74  2.59  [ 744 ] 
 Rivastigmine  20  29–64 
 (patch) 
 0.5  24  0.18  0.74  [ 391 ] 
 Drugs for treatment of substance related disorders 
 Acamprosate  24  1 741–4 221  1.0  24  0.16  0.40  [ 287 ] 
 Buprenorphin        no data available 
 Bupropion  17  2 500–11 300  1.0  24  0.06  0.28  [ 665 ] 
 Methadone  12  75–148  0.95  24  4.46  8.80  [ 474,727 ] 
 Naltrexone 
 6β-naltrexol 
 453  2 077–2 590 
 928–1 242 
 1.0  24  0.27 
 0.56 
 0.33 
 0.75 
 [ 182 ] 
 Varenicline  1 878  170–176  1.0  24  3.95  4.08  [ 540 ] 
 SPC: Summary of product characteristics; n.r.: not reported; active moiety: risperidone plus 9-hydroxyrisperidone; n: number of individuals; SD: standard deviation 
 Dose related ranges are obtained by multiplying C/D low and C/D high by the dose. Drugs listed in   ●  ▶   Table 5 were not included in this table, when clearance data were not 
 available from the literature. 
 Prepared by EH and CG, reviewed and supplemented by CH 
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by the daily dose. One must be aware, however, that many 
patients encountered in the clinical context do not fulfi l all the 
abovementioned conditions.
 Drug concentration in blood and brain
 The pharmacological activity of a psychotropic drug depends on 
its availability in the target organ, the brain. However, the latter 
is separated from the blood by 2 barriers, which have to be 
crossed by the drug, the blood-brain barrier (BBB) and the 
blood-cerebrospinal fl uid barrier  [ 154 ] . Most psychoactive drugs 
enter the brain due to their high lipid solubility by passive diﬀ u-
sion and thereby cross the barriers. The BBB is a physical barrier 
that separates circulating blood and the central nervous system, 
and it consists of endothelial cells around the capillaries joined 
together by tight junctions  [ 154 ] . It eﬃ  ciently restricts the 
exchange of solutes between the blood and the brain extracel-
lular fl uid. Functionally, it protects the brain against potentially 
harmful chemicals. As mentioned above, a number of psychoac-
tive drugs, such as risperidone, aripiprazole or venlafaxine are 
substrates of P-gp  [ 180 ,  370 ,  668 ] . As a consequence, brain to 
plasma concentration ratios vary widely for psychotropic drugs 
with similar physicochemical properties. Animal studies found 
ratios from 0.22 for risperidone  [ 29 ] to 34 for fl uphenazine  [ 27 ] . 
In spite of highly variable ratios of brain to plasma concentra-
tions of the diﬀ erent psychotropic drugs, animal studies have 
shown that steady-state plasma concentrations of psychoactive 
drugs correlate well with concentrations in brain, much better 
than doses. This has been shown for tricyclic antidepressants 
 [ 249 ] , trazodone  [ 173 ] , or olanzapine  [ 28 ] . Drug concentrations 
in plasma can therefore be considered as a valid surrogate 
marker of concentrations in brain.
 Drug concentration in blood and target structure 
occupancy in brain
 Positron emission tomography (PET) enables analysis of central 
nervous receptor occupancy in vivo  [ 207 ,  274 ,  275 ] . Antipsy-
chotic drugs exert most of their therapeutic actions by blockade 
of dopamine D2-like receptors. Blockade of D2 receptors by 
antipsychotic drugs reduces the binding of radioactive PET lig-
ands  [ 207 ,  272 ,  275 ] . Using this approach and quantifi cation of 
the displacement of dopamine receptor radioligands, it has been 
shown that plasma concentrations of antipsychotic drugs corre-
late well with receptor occupancy. In accordance with the high 
variability of drug concentrations in plasma under same doses it 
was found that receptor occupancy correlates better with plasma 
concentrations than with daily doses  [ 313 ] . Optimal response 
was seen at 70–80 % receptor occupancy, and 80 % receptor occu-
pancy was defi ned as the threshold for the occurrence of 
extrapyramidal side eﬀ ects  [ 207 ,  480 ] . PET was also used to 
characterize in vivo serotonin transporter occupancy by SSRIs 
 [ 442 ,  443 ] . Using a serotonin transporter radioligand, plasma 
concentrations of citalopram, paroxetine, fl uoxetine and sertra-
line were shown to correlate well with serotonin transporter 
occupancy. It was found that at least 80 % occupancy should be 
attained for optimal clinical outcome  [ 442 ,  443 ] . PET studies 
have thus brought about highly relevant information for the 
determination of optimal plasma concentrations of a consider-
able number of psychotropic drugs which is reviewed in this 
special issue by Gründer and co-workers  [ 274 ] .
 “Therapeutic window” – therapeutic reference range
 TDM is based on the assumption that there is a relationship 
between plasma concentrations and clinical eﬀ ects (therapeutic 
improvement, side eﬀ ects and adverse eﬀ ects). It also assumes 
that there is a plasma concentration range of the drug which is 
characterized by maximal eﬀ ectiveness and maximal safety, the 
so-called “therapeutic window”. Studies on relations between 
plasma concentration and clinical improvement have supported 
this concept since the sixties for lithium, tricyclic antidepres-
sants and classical antipsychotic drugs. Systematic reviews and 
meta-analyses that were based on adequately designed studies 
led to convincing evidence of a signifi cant relationship between 
clinical outcomes and plasma concentrations for nortriptyline, 
imipramine and desipramine which are associated with a high 
probability of response  [ 51 ] . For amitriptyline as a model com-
pound, a meta-analysis of 45 studies has shown that various sta-
tistical approaches provided almost identical results  [ 672 ,  674 ] . 
For new antipsychotic drugs like aripiprazole  [ 612 ] , olanzapine 
 [ 509 ] or risperidone  [ 737 ] relationships between plasma con-
centration and clinical eﬀ ectiveness have been reported.
 For the “therapeutic window” there are many synonymous 
terms like “therapeutic reference range”, “therapeutic range”, 
“optimal plasma concentration”, “eﬀ ective plasma concentra-
tion”, “target range”, “target concentration”, or “orienting thera-
peutic range”, the term used in the fi rst consensus  [ 51 ] . The 
present consensus uses the term “therapeutic reference range” 
in accordance with the guidelines on TDM for antiepileptic 
drugs  [ 499 ] . The “therapeutic reference range” was defi ned in 
this consensus guideline for neuropsychiatric drugs as follows:
 The therapeutic reference ranges as recommended by the TDM 
group of the AGNP are given in   ●  ▶   Table 5 . They were evidence-
based and derived from the literature by the structured review 
process described above. For only 15 neuropsychiatric drugs 
therapeutic reference ranges based on randomized clinical trials 
were found in the literature. For most drugs, reference ranges 
were obtained from studies with therapeutically eﬀ ective doses. 
Therefore, there is a need for further studies to defi ne therapeu-
tic ranges.
 The reference ranges listed in   ●  ▶   Table 5 are generally those for 
the primary indication. A number of drugs, however, are recom-
mended for several indications. For example, antidepressant 
drugs are also used for the treatment of anxiety states, and 
antipsychotic drugs are increasingly used to treat mania. Little 
information is available on optimum plasma concentrations in 
these situations. Exceptions are carbamazepine, lamotrigine and 
 Defi nition 
 The “ therapeutic reference ranges ” reported in this guide-
line (  ●  ▶   Table 5 ) defi ne ranges of medication concentrations 
which specify a  lower limit below which a drug induced 
therapeutic response is relatively unlikely to occur and an 
 upper limit above which tolerability decreases or above 
which it is relatively unlikely that therapeutic improvement 
may be still enhanced. The therapeutic reference range is an 
orienting, population based range which may not necessarily 
be applicable to all patients. Individual patients may show 
optimal therapeutic response under a drug concentration 
that diﬀ ers from the therapeutic reference range. Ultimately, 
psycho pharmacotherapy can be best guided by identifi cation 
of the patient’s “individual therapeutic concentration”. 
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68
   , 
 45
2   ,
  6
12
 ]    
  Th
e 
m
et
ab
ol
ite
 d
eh
yd
ro
ar
ip
ip
ra
zo
le
 is
 a
ct
iv
e 
in
 v
itr
o,
 it
 re
m
ai
ns
 
un
cl
ea
r t
o 
w
hi
ch
 e
xt
en
d 
it 
co
nt
rib
ut
es
 to
 c
lin
ic
al
 e
ﬀ e
ct
s  
  As
en
ap
in
e  
  2–
5 
ng
/m
L  
  24
 h
  
  10
 n
g/
m
L  
  4  
  3.
50
  
    [ 7
07
 ]    
  
  Be
np
er
id
ol
  
  1–
10
 n
g/
m
L  
  5 
h  
  20
 n
g/
m
L  
  3  
  2.
62
  
    [ 4
72
   ,  5
89
 ]    
  H
ig
he
r l
ev
el
s 
m
ay
 b
e 
to
le
ra
te
d 
in
 p
at
ie
nt
s 
un
de
r l
on
g-
te
rm
 h
ig
h-
do
se
 th
er
ap
y 
du
e 
to
 a
da
pt
iv
e 
ch
an
ge
s.
  
  Br
om
pe
rid
ol
  
  12
–1
5 
ng
/m
L  
  20
–3
6 
h  
  30
 n
g/
m
L  
  2  
  4.
38
  
    [ 6
09
   ,  6
56
   , 7
35
]  
  
  Ch
lo
rp
ro
m
az
in
e  
  30
–3
00
 n
g/
m
L  
  15
–3
0 
h  
  60
0 
ng
/m
L  
  2  
  3.
14
  
    [ 1
27
   ,  5
59
 ]    
  
  Ch
lo
rp
ro
th
ix
en
e  
  20
–3
00
 n
g/
m
L  
  8–
12
 h
  
  40
0 
ng
/m
L  
  3  
  3.
17
  
    [ 5
42
 ]    
  
  Cl
oz
ap
in
e  
  35
0–
60
0 
ng
/m
L  
  12
–1
6 
h  
  1 
00
0 
ng
/m
L  
  1  
  3.
06
  
    [ 1
75
   ,  5
07
   ,  4
93
   ,  5
07
   ,  6
78
 ]    
  M
aj
or
 m
et
ab
ol
ite
 N
-d
es
m
et
hy
lc
lo
za
pi
ne
 w
ith
 u
nc
le
ar
 a
nt
ip
sy
ch
ot
ic
 
ac
tiv
ity
  
  Fl
up
en
th
ix
ol
  
  1–
10
 n
g/
m
L  
  20
–4
0 
h  
  15
 n
g/
m
L  
  2  
  2.
30
  
    [ 4
0   ,
  5
43
   ,  5
64
 ]    
  
  Fl
up
he
na
zi
ne
  
  1–
10
 n
g/
m
L  
  16
 h
  
  15
 n
g/
m
L  
  1  
  2.
29
  
    [ 5
64
   ,  6
80
 ]    
  
  Fl
us
pi
ril
en
  
  0.
1–
2.
2 
ng
/m
L  
  7–
14
 d
ay
s  
  4.
4 
ng
/m
L  
  2  
  2.
10
  
    [ 6
11
 ]    
  
  H
al
op
er
id
ol
  
  1–
10
 n
g/
m
L  
  12
–3
6 
h  
  15
 n
g/
m
L  
  1  
  2.
66
  
    [ 7
4   ,
  2
14
   ,  4
80
   ,  4
94
   ,
  5
08
   ,  6
74
   ,  6
80
 ]    
  H
ig
he
r l
ev
el
s 
ca
n 
be
 to
le
ra
te
d 
in
 p
at
ie
nt
s 
un
de
r l
on
g-
te
rm
 h
ig
h-
do
se
 th
er
ap
y 
du
e 
to
 a
da
pt
iv
e 
ch
an
ge
s.
  
  Ilo
pe
rid
on
e  
  5–
10
 n
g/
m
l  
  18
–3
3 
h  
  20
 n
g/
m
l  
  3  
  2.
34
  
    [ 4
76
   ,  5
76
 ]    
  
  Le
vo
m
ep
ro
m
az
in
e  
  30
–1
60
 n
g/
m
L  
  16
–7
8 
h  
  32
0 
ng
/m
L  
  3  
  3.
04
  
    [ 6
56
 ]    
  
  M
el
pe
ro
ne
  
  30
–1
00
 n
g/
m
L  
  4–
6 
h  
  20
0 
ng
/m
L  
  3  
  3.
80
  
    [ 8
3   ,
  3
24
 ]    
  In
hi
bi
to
r o
f C
YP
2D
6  
  O
la
nz
ap
in
e  
  20
–8
0 
ng
/m
L  
  30
–6
0 
h  
  15
0 
ng
/m
L  
  1  
  3.
20
  
    [ 3
2   ,
  5
6   ,
  6
3   ,
  1
32
 ,  2
08
   ,  2
40
   ,
  4
18
   ,  4
78
   ,  5
09
   ,  6
02
   ,  7
11
 ]    
  U
nd
er
 o
la
nz
ap
in
e 
pa
m
oa
te
, p
at
ie
nt
s 
ex
hi
bi
te
d 
a 
po
st
 in
je
ct
io
n 
sy
nd
ro
m
e 
w
he
n 
dr
ug
 c
on
ce
nt
ra
tio
ns
 e
xc
ee
de
d 
15
0 
ng
/m
L  
  Pa
lip
er
id
on
e  
  20
–6
0 
 n
g/
m
L  
  23
 h
  
  12
0 
ng
/m
L  
  2  
  2.
35
  
    [ 2
6   ,
  7
0   ,
  1
31
   ,  4
66
 ]    
  Pa
lip
er
id
on
e 
= 
9-
hy
dr
ox
yr
isp
er
id
on
e  
  Pe
ra
zi
ne
  
  10
0–
23
0 
ng
/m
L  
  8–
16
 h
  
  46
0 
ng
/m
L  
  1  
  2.
95
  
    [ 9
1 ]
    
  
  Pe
rp
he
na
zi
ne
  
  0.
6–
2.
4 
ng
/m
L  
  8–
12
 h
  
  5 
ng
/m
L  
  1  
  2.
48
  
    [ 5
64
   ,  6
37
   ,  6
80
 ]    
  
  Pi
m
oz
id
e  
  15
–2
0 
ng
/m
L  
  23
–4
3 
h  
  20
 n
g/
m
L  
  3  
  2.
17
  
    [ 6
49
 ]    
  
  Pi
pa
m
pe
ro
ne
  
  10
0–
40
0 
ng
/m
L  
  17
–2
2 
h  
  50
0 
ng
/m
L  
  3  
  2.
66
  
    [ 8
2   ,
  5
17
 ]    
  
  Pr
ot
hi
pe
nd
yl
  
  5–
10
 n
g/
m
L  
  2–
3 
h  
  20
 n
g/
m
L  
  4  
  3.
35
  
    [ 4
36
] S
PC
     
  
  Q
ue
tia
pi
ne
  
  10
0–
50
0 
ng
/m
L  
  7 
h  
  1 
00
0 
ng
/m
L  
  2  
  2.
61
  
    [ 1
12
   ,  2
12
   ,  2
36
   ,  2
99
   ,  4
98
   , 
 60
3   ,
  6
27
   ,  6
89
   ,  7
23
 ]    
  W
he
n 
th
e 
pa
tie
nt
 h
as
 ta
ke
n 
th
e 
ex
te
nd
ed
 re
le
as
e 
(X
R)
 fo
rm
ul
at
io
n 
in
 th
e 
ev
en
in
g 
an
d 
bl
oo
d 
w
as
 w
ith
dr
aw
n 
in
 th
e 
m
or
ni
ng
, e
xp
ec
te
d 
pl
as
m
a 
co
nc
en
tr
at
io
ns
 a
re
 2
-fo
ld
 h
ig
he
r t
ha
n 
tr
ou
gh
 le
ve
ls
  
  Ri
sp
er
id
on
e 
 pl
us
 9
-h
yd
ro
xy
ris
pe
rid
on
e  
    20
–6
0 
ng
/m
L  
  3 
h 
 24
 h
  
  12
0 
ng
/m
L  
  2  
  2.
44
 
 2.
35
  
    [ 1
50
   ,  4
06
   ,  4
26
   ,  4
37
   ,  4
69
   ,  4
75
   ,  
55
3   ,
  5
57
   ,  6
17
   , 7
29
,7
37
]  
  
  Se
rt
in
do
le
  
  50
–1
00
 n
g/
m
L  
  55
–9
0 
h  
  20
0 
ng
/m
L  
  2  
  2.
27
  
    [ 7
1   ,
  1
09
   ,  1
10
   ,  6
53
   , 7
28
,7
29
]  
  Ac
tiv
e 
m
et
ab
ol
ite
 d
eh
yd
ro
se
rt
in
do
le
 (c
on
ce
nt
ra
tio
n 
at
 th
er
ap
eu
tic
 
do
se
s 
40
–6
0 
ng
/m
L)
, c
on
ce
nt
ra
tio
n 
de
pe
nd
en
t i
nc
re
as
e 
of
 Q
T 
in
te
rv
al
 b
y 
bl
oc
ka
de
 o
f p
ot
as
si
um
 c
ha
ne
ls
  
  Su
lp
iri
de
  
  20
0–
1 
00
0 
ng
/m
L  
  8–
14
 h
  
  1 
00
0 
ng
/m
L  
  2  
  2.
93
  
    [ 4
60
   ,  6
56
 ]    
  N
o 
m
et
ab
ol
ite
s,
 re
na
l e
lim
in
ia
tio
n  
  Th
io
rid
az
in
e  
  10
0–
20
0 
ng
/m
L  
  30
 h
  
  40
0 
ng
/m
L  
  1  
  2.
70
  
    [ 1
90
   ,  6
56
 ]    
  Co
nt
ra
in
di
ca
te
d 
in
 p
oo
r m
et
ab
ol
iz
er
s 
of
 C
YP
2D
6  
  Zi
pr
as
id
on
e  
  50
–2
00
 n
g/
m
L  
  6 
h  
  40
0 
ng
/m
L  
  2  
  2.
55
  
    [ 1
26
   ,  4
19
   ,  4
27
   ,  6
88
   ,  6
95
 ]    
  Th
e 
dr
ug
 s
ho
ul
d 
be
 ta
ke
n 
w
ith
 a
 m
ea
l, 
ot
he
rw
is
e 
ab
so
rp
tio
n 
is
 
re
du
ce
d 
an
d 
pl
as
m
a 
co
nc
en
tr
at
io
ns
 w
ill
 b
e 
lo
w
er
 th
an
 e
xp
ec
te
d  
  Zo
te
pi
ne
  
  10
–1
50
 n
g/
m
L  
  13
–1
6 
h  
  30
0 
ng
/m
L  
  3  
  3.
01
  
    [ 3
76
   ,  6
42
 ]    
  
  Zu
cl
op
en
tix
ol
  
  4–
50
 n
g/
m
L  
  15
–2
5 
h  
  10
0 
ng
/m
L  
  3  
  2.
49
  
    [ 3
30
   ,  3
71
   ,  6
92
 ]    
  
  Pl
as
m
a 
co
nc
en
tr
at
io
ns
 g
iv
en
 in
 m
as
s 
un
its
 c
an
 b
e 
co
nv
er
te
d 
to
 m
ol
ar
 u
ni
ts
 b
y 
m
ul
tip
lic
at
io
n 
w
ith
 th
e 
co
nv
er
si
on
 fa
ct
or
 (C
F)
 n
m
ol
/L
 =
 n
g/
m
L 
x 
CF
  
   &  A
ct
iv
e 
m
et
ab
ol
ite
 c
on
tr
ib
ut
es
 to
 w
an
te
d 
an
d 
un
w
an
te
d 
eﬀ
 e
ct
s.
 In
di
ca
te
d 
re
fe
re
nc
e 
ra
ng
es
 a
nd
 la
bo
ra
to
ry
 a
le
rt
 le
ve
ls
 re
fe
r t
o 
th
e 
m
ot
he
r c
om
po
un
d 
on
ly
.  
  Fo
r b
up
ro
pi
on
, c
ar
ba
m
az
ep
in
e,
 la
m
ot
rig
in
e 
an
d 
va
lp
ro
ic
 a
ci
d 
re
co
m
m
en
de
d 
re
fe
re
nc
e 
ra
ng
es
 w
er
e 
lis
te
d 
tw
ic
e 
in
 a
cc
or
da
nc
e 
w
ith
 th
e 
2 
di
ﬀ e
re
nt
 in
di
ca
tio
ns
.  
  Pr
ep
ar
ed
 b
y 
CH
, P
B,
 S
U
, B
R 
an
d 
H
K,
 re
vi
ew
ed
 b
y 
AC
, O
D
, K
E,
 M
F,
 M
G
, C
G
, G
G
, E
H
, U
H
-R
, C
H
, E
JS
, H
K,
 G
L,
 U
L,
 T
M
, B
P,
 B
S,
 M
U
, S
U
, G
Z  
Co
nt
in
ue
d.
D
ow
nl
oa
de
d 
by
: B
ib
lio
th
èq
ue
 C
an
to
na
le
 e
t U
ni
ve
rs
ita
ire
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
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  Ta
bl
e 
5   
 Re
co
m
m
en
de
d 
re
fe
re
nc
e 
ra
ng
es
, l
ab
or
at
or
y 
al
er
t l
ev
el
s 
an
d 
le
ve
ls
 o
f r
ec
om
m
en
da
tio
n 
fo
r T
D
M
. 
  D
ru
gs
 a
nd
 a
ct
iv
e 
 m
et
ab
ol
ite
s  
  Th
er
ap
eu
tic
 re
fe
re
nc
e 
ra
ng
e/
re
co
m
m
en
de
d 
dr
ug
 
co
nc
en
tr
at
io
n  
  t1
/2
  
  La
bo
ra
to
ry
 
al
er
t l
ev
el
  
  Le
ve
l o
f r
ec
om
m
en
-
da
tio
n 
to
 u
se
 T
D
M
 
(c
on
se
ns
us
)  
  Co
nv
er
si
on
 
fa
ct
or
  (
CF
, 
se
e 
be
lo
w
)  
  Re
fe
re
nc
e  
  Co
m
m
en
ts
  
   M
oo
d 
st
ab
ili
zi
ng
 d
ru
gs
   
  Ca
rb
am
az
ep
in
e    
  4–
10
 μ
g/
m
L  
  10
–2
0 
h  
  20
 μ
g/
m
L  
  2  
  4.
23
  
    [ 5
12
 ]    
  Ac
tiv
e 
10
,1
1-
ep
ox
id
e 
m
et
ab
ol
ite
 c
on
tr
ib
ut
es
 to
 c
lin
ic
al
 e
ﬀ e
ct
s  
  La
m
ot
rig
in
e  
  3–
14
 μ
g/
m
L  
  7–
23
 h
  
  30
 μ
g/
m
L  
  2  
  3.
90
  
    [ 4
55
   ,  5
58
 ]    
  So
 fa
r n
o 
sp
ec
ifi 
c 
re
fe
re
nc
e 
ra
ng
 fo
r m
oo
d 
st
ab
ili
zi
ng
 e
ﬀ e
ct
, 
 va
lp
ro
at
e 
in
cr
ea
se
s 
el
im
in
at
io
n 
ha
lf 
lif
e 
to
 4
8–
70
 h
  
  Li
th
iu
m
  
  0.
5–
1.
2 
m
m
ol
/l 
 (4
–8
 μ
g/
m
L)
  
  24
 h
  
  1.
2 
m
m
ol
/l 
 (8
 μ
g/
m
L)
  
  1  
  12
5.
8  
    [ 5
93
   ,  7
21
 ]    
  Ag
e 
de
pe
nd
en
t i
nc
re
as
e 
of
 e
lim
in
at
io
n 
ha
lf 
lif
e  
  Va
lp
ro
ic
 a
ci
d  
  50
–1
00
 μ
g/
m
L  
  18
 h
  
  12
0 
μg
/m
L  
  2  
  6.
93
  
    [ 1
6   ,
  2
16
   ,  3
01
   ,  6
83
 ]    
  In
 in
di
vi
du
al
 c
as
es
 1
20
μg
/m
L 
ar
e 
al
so
 to
le
ra
te
d 
in
 a
cu
te
 m
an
ia
.  
   An
tic
on
vu
ls
an
t d
ru
gs
   
  Ca
rb
am
az
ep
in
e  
  4–
12
 μ
g/
m
L  
  10
–2
0 
h  
  20
 μ
g/
m
L  
  2  
  4.
25
  
    [ 8
7   ,
  3
38
   ,  4
99
 ]    
  Ac
tiv
e 
10
,1
1-
ep
ox
id
e 
m
et
ab
ol
ite
 c
on
tr
ib
ut
es
 to
 c
lin
ic
al
 e
ﬀ e
ct
s  
  Cl
ob
az
am
 a
nd
 
 N
-d
es
m
et
hy
lc
lo
ba
za
m
  
  30
–3
00
 n
g/
m
L 
 30
0–
3 
00
0 
ng
/m
L  
  18
–4
2 
h  
  50
0 
ng
/m
L 
 5 
00
0 
ng
/m
L  
  2  
  3.
33
 
 3.
49
  
    [ 2
78
   ,  4
99
 ]    
  Ac
tiv
e 
N
-d
em
et
hy
la
te
d 
m
et
ab
ol
ite
 c
on
tr
ib
ut
es
 to
 c
lin
ic
al
 e
ﬀ e
ct
s  
  Cl
on
az
ep
am
  
  20
–7
0 
ng
/m
L  
  40
 h
  
  80
 n
g/
m
L  
  2  
  3.
17
  
    [ 4
4   ,
  4
64
   ,  4
99
 ]    
  7-
Am
in
o 
m
et
ab
ol
ite
 re
ta
in
s 
so
m
e 
ac
tiv
ity
  
  Et
ho
su
xi
m
id
e  
  40
–1
00
 μ
g/
m
L  
  33
–5
5 
h  
  12
0 
μg
/m
L  
  2  
  7.
08
  
    [ 8
8   ,
  4
99
 ]    
  
  Fe
lb
am
at
e  
  30
–6
0 
μg
/m
L  
  15
–2
3 
h  
  10
0 
μg
/m
L  
  2  
  4.
20
  
    [ 2
90
   ,  3
43
   ,  4
99
 ]    
  
  G
ab
ap
en
tin
  
  2–
20
 μ
g/
m
L  
  6 
h  
  25
 μ
g/
m
L  
  3  
  5.
84
  
    [ 7
5      –
 77
   ,  3
43
   ,  3
98
   ,  4
99
 ]    
  
  La
co
sa
m
id
e  
  1–
10
 μ
g/
m
L  
  13
 h
  
  20
 μ
g/
m
L  
  
  2.
66
  
    [ 4
7 ]
    
  
  La
m
ot
rig
in
e  
  3–
14
 μ
g/
m
L  
  7–
23
 h
  
  20
 μ
g/
m
L  
  2  
  3.
90
  
    [ 8
8   ,
  3
43
   ,  4
55
   ,  4
56
   ,  4
99
   ,  6
10
 ]    
  Va
lp
ro
at
e 
in
cr
ea
se
s 
el
im
in
at
io
n 
ha
lf 
lif
e 
to
 4
8–
70
 h
  
  Le
ve
tir
ac
et
am
  
  10
–4
0 
μg
/m
L  
  6–
8 
h  
  10
0 
μg
/m
L 
 (m
or
ni
ng
 
le
ve
ls
)  
  2  
  3.
87
  
    [ 8
8   ,
  3
43
   ,  4
30
   ,  4
99
 ]    
  
  M
et
hs
ux
im
id
e 
pl
us
 
m
et
hs
ux
im
id
e  
  10
–4
0 
μg
/m
L  
  1–
3 
h 
 36
–4
5 
h  
  45
 μ
g/
m
L  
  2  
  4.
92
 a
nd
 
 5.
29
  
    [ 8
8 ]
    
  Th
e 
m
et
ab
ol
ite
 is
 th
e 
ac
tiv
e 
pr
in
ci
pl
e 
in
 v
iv
o  
  O
xc
ar
ba
ze
pi
ne
 p
lu
s 
 10
-h
yd
ro
xy
ca
rb
az
ep
in
e  
  10
–3
5 
μg
/m
L  
  5 
h 
 10
–2
0 
h  
  40
 μ
g/
m
L  
  2  
  3.
96
   a
nd
 
 3.
73
  
    [ 8
8   ,
  3
43
   ,  4
28
   ,  4
99
 ]    
  
  Ph
en
ob
ar
bi
ta
l  
  10
–4
0 
μg
/m
L  
  80
–1
20
 h
  
  50
 μ
g/
m
L  
  1  
  4.
31
  
    [ 8
8   ,
  4
99
 ]    
  
  Ph
en
yt
oi
n  
  10
–2
0 
μg
/m
L  
  20
–6
0 
h  
  25
 μ
g/
m
L  
  1  
  3.
96
  
    [ 8
8   ,
  3
80
   ,  4
99
 ]    
  
  Pr
eg
ab
al
in
  
  2–
5 
μg
/m
L  
  6 
h  
  10
 μ
g/
m
L  
  3  
  6.
28
  
    [ 6
8   ,
  7
7   ,
  8
8   ,
  3
43
   ,  4
32
   ,  4
99
 ]    
  
  Pr
im
id
on
e 
(a
ct
iv
e 
 m
et
ab
ol
ite
 p
he
no
ba
rb
ita
l)  
  5–
10
 μ
g/
m
L  
  14
–1
5 
h  
  25
 μ
g/
m
L  
  2  
  4.
58
  
    [ 8
8   ,
  4
99
 ]    
  D
at
a 
gi
ve
n 
ar
e 
re
st
ric
te
d 
to
 p
rim
id
on
e,
 fo
r t
he
 a
ct
iv
e 
m
et
ab
ol
ite
 
ph
en
ob
ar
bi
ta
l r
ec
om
m
en
de
d 
pl
as
m
a 
co
nc
en
tr
at
io
ns
 a
re
 
10
–4
0 
μg
/m
L  
  Ru
fi n
am
id
  
  5–
30
 μ
g/
m
L  
  7 
h  
  40
 μ
g/
m
L  
  2  
  4.
20
  
    [ 5
11
 ]    
  
  St
iri
pe
nt
ol
  
  1–
10
 μ
g/
m
L  
  4–
13
 h
  
  15
 μ
g/
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valproic acid, which are therefore listed twice in   ●  ▶   Table 5 . 
Moreover, it should be mentioned that studies are on the way to 
evaluate therapeutic reference ranges for children or adolescent 
patients and for elderly patients.
 Estimation of the lower limit of the therapeutic reference 
range 
 Estimation of a therapeutic reference range (TRR) requires esti-
mation of a lower and an upper limit of drug concentration in 
plasma. A generally accepted method for calculation of these 
limits does not exist. Whenever possible the lower limit of a 
drug’s therapeutic range should be based on studies on the rela-
tionship between a drug’s plasma concentration and clinical 
eﬀ ectiveness. Below this limit, therapeutic eﬀ ects are not sig-
nifi cantly diﬀ erent from placebo. The optimum study design for 
evaluation of the lower limit of the therapeutic range is a pro-
spective double-blind study where patients are treated with 
drug doses which lead to a defi ned plasma concentration range 
of the drug. Such a design was applied by Van der Zwaag and co-
workers for patients treated with clozapine  [ 678 ] . Patients were 
titrated to 3 diﬀ erent plasma concentrations of the antipsychotic 
drug. Signifi cant superiority was found in patients with middle 
and high plasma concentration compared with low concentra-
tions of clozapine. A similar design was applied for a blood-level 
study comparing imipramine and mirtazapine  [ 98 ] . To conduct 
such studies, however, is a considerable logistic challenge. Fixed 
dose studies are therefore preferred for evaluation of the lower 
limit of the therapeutic reference range  [ 672 ,  674 ] .
 For the estimation of threshold values of the therapeutic refer-
ence range, receiver operating characteristic (ROC) analysis has 
proven helpful  [ 289 ] . A ROC plot allows the identifi cation of a 
cut-oﬀ  value that separates responders from non-responders 
and estimates the sensitivity and specifi city of the parameter 
“medication plasma concentration”. The usefulness of the ROC 
analysis has been demonstrated for a number antipsychotic and 
antidepressant drugs  [ 461 ,  505 ,  510 ,  703 ] .
 Estimation of the upper limit of the therapeutic 
reference range 
 In the fi rst study on TDM in psychiatry  [ 31 ] an U-shaped rela-
tionship between plasma concentration and clinical eﬀ ect was 
reported for nortriptyline. The lack of eﬀ ect at high concentra-
tions was attributed to the mechanism of action of the tricyclic 
antidepressant drug on monoaminergic neurons. According to 
actual knowledge, however, it seems more likely that reduced 
amelioration at high concentrations is due to side eﬀ ects. The 
upper limit of the therapeutic range is therefore defi ned by the 
occurrence of side eﬀ ects, also in this guideline. For most side 
eﬀ ects (type A adverse reactions), it is also assumed that they 
are a function of dose and drug concentration in the body  [ 335 ] . 
This assumption has been confi rmed for motor side eﬀ ects of 
antipsychotic drugs  [ 536 ] and for unwanted side eﬀ ects of tri-
cyclic antidepressant drugs  [ 153 ,  282 ] . For paroxetine, a positive 
correlation was found between drug concentration in plasma 
and serotonin syndrome symptoms  [ 303 ] . When such data are 
available, it is possible to apply ROC analysis for the calculation 
of the upper limit of the therapeutic range  [ 461 ] . For many psy-
chotropic drugs listed in   ●  ▶   Table 5 , however, valid data on both 
plasma concentration and the incidence of side eﬀ ects are lack-
ing. Case reports on tolerability problems or intoxications do 
often not include drug concentration measurements in plasma. 
Sporadic reports on fatal cases and intoxications are of limited 
value. Most blood concentrations reported to have caused death 
are far above drug concentrations that are associated with maxi-
mum therapeutic eﬀ ects  [ 544 ,  622 ] . Post mortem redistribution 
of medications from or into the blood can lead to dramatic 
changes in blood levels  [ 382 ,  518 ] , and the direction of the 
change does not follow a general rule  [ 359 ] . Estimation of an 
upper threshold level above which tolerability decreases or the 
risk of intoxication increases is therefore more diﬃ  cult than 
estimation of the lower threshold level, especially for drugs with 
a broad therapeutic index like SSRIs.
 Estimation and defi nition of a laboratory alert level 
 As explained above, plasma concentrations with an increased 
risk of toxicity are normally much higher than the upper thresh-
old levels of the therapeutic reference ranges for most psycho-
tropic drugs shown in   ●  ▶   Table 5 . For the present guidelines, we 
therefore defi ned an upper plasma concentration limit above 
which it seems unlikely that therapeutic eﬀ ects may be enhanced 
and added a “laboratory alert level” which was defi ned as  follows:
 From population-based to subject-based reference values 
 All therapeutic reference ranges listed in   ●  ▶   Table 5 are orienting, 
population-based ranges. The population-derived ranges consti-
tute descriptive statistical values which may not necessarily be 
applicable to all patients. Individual patients may show the 
 optimum therapeutic response under a drug concentration that 
diﬀ ers from the therapeutic reference range. Psychopharmaco-
therapy should therefore try to identify a patient’s “individual 
therapeutic concentration” to guide the treatment  [ 61 ,  523 ] . For 
lithium it has been shown that the recommended plasma con-
centration range depends on whether the patient is in an acute 
manic episode or needs maintenance therapy  [ 593 ] . For cloza-
pine, Gaertner and colleagues  [ 232 ] determined optimal plasma 
concentrations required for stable remission of individual 
patients under maintenance therapy in a relapse prevention 
study.
 Recommendations for measuring plasma 
concentrations of psychoactive drugs
 The usefulness of TDM varies with the clinical situation and the 
particular drug involved. In case of suspected non-adherence to 
medication or intoxications, quantifying plasma concentrations 
is a generally accepted tool for all drugs and groups of patients. 
However, it is still a matter of debate if TDM should be imple-
 Defi nition 
 The  “laboratory alert levels” reported in this guideline 
(  ●  ▶   Table 5 ) indicate drug concentrations above the recom-
mended reference range that causes the laboratory to feed-
back immediately to the prescribing physician. The alert 
levels are based on reports on intolerance or intoxications 
and plasma concentration measurements. In most cases, 
however, it was arbitrarily defi ned as a plasma concentration 
that is 2-fold higher than the upper limit of the therapeutic 
reference range. The laboratory alert should lead to dose 
reduction when the patient exhibits signs of intolerance or 
toxicity. When the high drug concentration is well tolerated 
by the patient and if dose reduction bears the risk of symp-
tom exacerbation, the dose should remain unchanged. The 
clinical decision, especially in case of unchanged dose needs 
to be documented in the medical fi le. 
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mented in clinical routine. Based on empirical evidence, 5 levels 
of recommendation to use TDM were defi ned in the guidelines 
2004 for 65 psychotropic drugs. These defi nitions were revised 
and grading reduced to 4 levels of recommendation, now  ranging 
from “strongly recommended” to “potentially useful” as  follows:
 According to our literature-based evaluations, TDM was graded 
as “strongly recommended” for 15 of the 128 surveyed neuro-
psychiatric compounds, “recommended” for 52 medications, 
“useful” for 44 drugs and “potentially useful” for 19 drugs 
(  ●  ▶   Table 5 ).
 TDM is highly recommended for most tricyclic  antidepressants . 
It reduces the risk of intoxications  [ 103 ,  381,  459 ,  510, 525 , 527 , 
 528 ,  530,  718 ] , and for many tricyclic antidepressants, a plasma 
concentration – clinical eﬀ ectiveness relationship has been 
shown. For SSRIs, TDM is of little clinical importance in clinical 
practice  [ 6 ,  537 ,  644 ] . Toxicity of this type of antidepressants is 
low in comparison to most of the pre-SSRI antidepressants 
 [ 48 ,  166 ,  314 ,  646 ,  715 ] . Data from Sweden revealed that TDM of 
SSRIs is cost-eﬀ ective in elderly patients where it helped to use 
minimum eﬀ ective doses  [ 410 ] . For citalopram a recent obser-
vational study revealed that plasma concentrations on day 7 of 
treatment are predictive for later non-response  [ 491 ] . Patients 
exhibiting citalopram plasma concentrations below 50 ng/mL 
had a signifi cantly reduced improvement on the Hamilton rating 
scale for depression. Evidence for a statistically signifi cant rela-
tionship between drug concentration and therapeutic outcome 
is lacking for the tetracyclic antidepressants maprotiline, mian-
serin and mirtazapine and also for trazodone and reboxetine, 
the monoamine oxidase inhibitors moclobemide and tranylcy-
promine.
 TDM is strongly recommended for the  typical antipsychotic 
drugs haloperidol, perphenazine and fl uphenazine, and for the 
atypical antipsychotics amisulpride, clozapine, olanzapine, and 
risperidone (  ●  ▶   Table 5 ). Overdosing may lead to extrapyramidal 
side eﬀ ects. In the case of clozapine, there is a strong correlation 
between clozapine plasma levels and incidence of seizures. 
Avoiding overdosing of typical antipsychotic drugs by TDM is for 
the majority of patients a matter of quality of life rather than 
safety  [ 136 ] . TDM of antipsychotics is also useful when medica-
tion is switched from the oral to the depot form, or vice versa.
 With regard to the  mood stabilizing and/or  antimanic drugs 
lithium, valproic acid and carbamazepine, therapeutic reference 
ranges and toxic levels are well defi ned. Therefore TDM is 
strongly recommended for these drugs (  ●  ▶   Table 5 ). For lithium 
TDM is even the standard of care  [ 133 ,  170 ,  185 ,  280 ,  395 ,  593 , 
 706 ,  721 ] . For its long-term use, plasma concentrations of 0.5–
0.8 nmol/L are advised. For an acute treatment with lithium, it 
may be justifi ed to increase its concentrations up to 1.2 mmol/L.
 Compounds that have been shown to be eﬀ ective as  antidemen-
tia drugs are donepezil, rivastigmine, galantamine and meman-
tine. TDM is rarely used for the treatment of dementia, though 
there is evidence that it can be useful. For donepezil, it has been 
shown that the patients’ improvement was signifi cantly better if 
their plasma concentrations were above 50 ng/mL as compared 
to patients that showed lower drug concentrations  [ 563 ] .
 Most  anxiolytic and  hypnotic drugs belong to the class of ben-
zodiazepines. Anxiolytic and hypnotic eﬀ ects are rapid. Treat-
ment can therefore be guided by immediate clinical impression 
rather than by TDM. In case of lack of therapeutic eﬀ ects under 
usual doses, however, TDM may clarify if non-response was due 
to drug abuse that has led to tolerance or due to pharmacoki-
netic abnormalities. For alprazolam, TDM may be useful to sup-
press panic attacks  [ 722 ] .
 The  opiate agonists methadone, R-methadone (levometha-
done), buprenorphine, l-α-acetylmethadol (LAAM) and slow-
release formulations of morphine are used for the treatment of 
opioid addiction. TDM is indicated for patients treated with 
methadone or R-methadone. The usefulness of TDM for moni-
toring treatment with “anti-craving” medications such as acam-
prosate or naltrexone, employed for the treatment of alcohol use 
disorders, has recently been reviewed elsewhere  [ 99 ] . TDM was 
recommended to enhance the moderate eﬃ  cacy of these drugs.
 Defi nitions 
 Level 1: Strongly recommended 
 Evidence: Reported drug concentrations are established and 
evaluated therapeutic reference ranges. Controlled clinical 
trials have shown benefi cial eﬀ ects of TDM, reports on 
decreased tolerability or intoxications. 
 Recommendation: TDM is strongly recommended for dose 
titration and for special indications. For lithium, TDM is a 
standard of care. 
 Clinical consequences: At therapeutic plasma concentrations 
highest probability of response or remission; at “subthera-
peutic” plasma concentrations: response rate similar to pla-
cebo under acute treatment and risk of relapse under chronic 
treatment; at “supratherapeutic” plasma concentrations: risk 
of intolerance or intoxication. 
 Level 2: Recommended 
 Evidence: Reported drug concentrations were obtained from 
plasma concentrations at therapeutically eﬀ ective doses and 
related to clinical eﬀ ects; reports on decreased tolerability or 
intoxications at “supratherapeutic” plasma concentrations. 
 Recommendation: TDM is recommended for dose titration 
and for special indications or problem solving. 
 Clinical consequences: TDM will increase the probability of 
response in non-responders. At “subtherapeutic” plasma 
concentrations: risk of poor response; at “supratherapeutic” 
plasma concentrations: risk of intolerance or intoxication. 
 Level 3: Useful 
 Evidence: Reported drug concentrations were calculated 
from plasma concentrations at eﬀ ective doses obtained from 
pharmacokinetic studies. Plasma concentrations related to 
pharmacodynamic eﬀ ects are either not yet available or 
based on retrospective analysis of TDM data, single case 
reports or non-systematic clinical experience. 
 Recommendation: TDM is useful for special indications or 
problem solving. 
 Clinical consequences: TDM can be used to control whether 
plasma concentrations are plausible for a given dose, or clini-
cal improvement may be attained by dose increase in non-
responders who display too low plasma concentrations. 
 Level 4: Potentially useful 
 Evidence: Plasma concentrations do not correlate with clini-
cal eﬀ ects due to unique pharmacology of the drug, e. g., irre-
versible blockade of an enzyme, or dosing can be easily 
guided by clinical symptoms, e. g., sleep induction by a hyp-
notic drug. 
 Recommendation: TDM is not recommended for dose titra-
tion but may be potentially useful for special indications or 
problem solving. 
 Clinical consequences: TDM should be restricted to special 
indications. 
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 For  anticonvulsant drugs , TDM is well established, especially 
for old drugs which are more toxic than the new ones  [ 499 ] .
 For  antiparkinson drugs , TDM has not been established so far. 
For the dopamine agonists, data on reference ranges are scarce. 
For L-dopa, there is an imperfect correlation between plasma 
concentrations and short-term clinical response  [ 479 ] . Never-
theless, we considered the pharmacologic properties of these 
neurological drugs (  ●  ▶   Table 1 ,  5 ), since psychiatric patients may 
receive antiparkinson drugs that possibly interfere with the 
action of psychotropic medication. For most of these drugs 
Cmax values are given.
 Indications for measuring plasma concentrations of 
psychoactive drugs
  ●  ▶   Table 6 presents a list of indications for TDM in psychiatry. 
The validity of these indications has to be examined on an indi-
vidual basis and evaluated for each case individually. Similar to 
any diagnostic test, TDM should only be requested when there is 
evidence that the result will provide an answer to a well defi ned 
question.
 For drugs with well defi ned therapeutic reference ranges or with 
a narrow therapeutic index it makes sense to measure plasma 
levels for dose titration after initial prescription or after dose 
change. Even without a specifi c problem, there is suﬃ  cient evi-
dence that TDM has benefi cial eﬀ ects for patients treated with 
these drugs. This holds true for lithium, tricyclic antidepres-
sants, several antipsychotics or anticonvulsants (  ●  ▶   Table 5 ). For 
lithium, TDM is even mandatory for safety reasons.
 In case of  suspected non-adherence or lack of clinical improve-
ment under recommended doses: TDM is a valid tool for treat-
ment with all drugs considered in these guidelines. Loss of 
adherence is a major problem of long-term medication 
 [ 10 ,  55 ,  401 ] . In patients with schizophrenia  [ 55 ,  351 ] and in 
patients with unipolar or bipolar disorders non-adherence 
ranges from 10 to 69 %  [ 401 ,  439 ] . Methods used to measure 
adherence include pill counting, examining case-note record-
ings, interviewing patients or noting the attending physicians’ 
clinical judgement about adherence  [ 11 ,  355 ,  685 ,  708 ] . Studies 
have shown that clinicians cannot reliably predict their patients’ 
adherence  [ 104 ,  579 ] . TDM is advantageous, since it is an objec-
tive method and tells the prescribing physician if the drug is in 
the body at a concentration that is potentially suﬃ  cient for the 
expected clinical response. Deviations from the expected dose-
related reference range (  ●  ▶   Table 4 ) indicate if the patient has 
taken his/her medication, and concomitant determination of 
metabolites is another approach to clarify if the drug was taken 
continuously as recommended. For interpretation, however, 
possible interactions with co-medications exhibiting enzyme 
inhibiting or inducing properties must be considered (  ●  ▶   Table  3 ). 
Reis and coworkers  [ 546 ,  547 ] analysed the compliance of 
patients who were treated with sertraline by repeated determi-
nation of serum drug concentrations of the parent compound 
and of the metabolite. Variations of the ratios of concentrations 
of norsertraline to sertraline were highly indicative for hidden 
and partial non-adherence. To be able to use this approach, these 
guidelines were supplemented with data on ratios of concentra-
tions for 32 psychoactive drugs (  ●  ▶   Table 2 ). By taking several 
blood samples per day and by calculation the observed and 
expected time dependent plasma concentrations it can be dif-
ferentiated if a low plasma concentration is due to reduced bio-
availability, enhanced degradation or poor adherence. 
Pharmacokinetic modelling of the expected time dependent 
plasma concentration thereby considers a drug’s basic pharma-
cokinetic properties  [ 4 ,  78 ,  340 ,  626 ,  654 ] .
 When  clinical improvement under recommended doses is 
 insuﬃ  cient and the drug is well tolerated, TDM will clarify if the 
drug concentration is too low and if it makes sense to increase 
the dose.
 When  adverse eﬀ ects are associated with clinical improvement 
under recommended doses, measurement of the plasma con-
centration may clarify if side eﬀ ects are related to excessively 
high drug levels in the blood and if the dose should be decreased.
 When  combining medications that are inhibitors or inducers of 
drug metabolizing enzymes (  ●  ▶   Table 1 ), pharmacokinetic drug 
interactions will occur if the comedication is a substrate of the 
inhibited or induced enzyme (  ●  ▶   Table 3 ). Dose adaptation 
should be guided by TDM in combination with an inducer or 
inhibitor and avoid loss of action, poor tolerability or intoxica-
tion due to a pharmacokinetic drug-drug interaction 
 [ 215 ,  244 ,  594 ] . With regard to environmental factors smoking is 
of high clinical relevance for drugs that are substrates of CYP1A2 
(  ●  ▶   Table 1 ). The isoenzyme is dose dependently induced by con-
stituents of cigarette smoke (polycyclic aromatic hydrocarbons, 
not nicotine). Its activity increases by 1.2-fold, 1.5-fold for 1.7-
fold for 1–5, 6–10 and  > 10 cigarettes smoked per day  [ 201 ] . On 
the other hand, CYP1A2 activity decreases until the fourth day 
immediately on cessation of heavy smoking  [ 200 ] . Smoking 
eﬀ ects should therfore be considered when patients are under 
therapy with a CYP1A2 substrate (  ●  ▶   Table 1 ) such as clozapine 
 [ 81 ,  676 ] , duloxetine  [ 222 ] or olanzapine  [ 749 ] . It should also be 
mentioned that many pharmacokinetic drug-drug interactions 
have been found by TDM either by chance or by retrospective 
analysis of TDM data bases  [ 112 ,  537 ] .
 In  pharmacovigilance programs , the safety of drug use is 
supervised under naturalistic conditions  [ 271 ,  285 ] . In case of 
observed adverse events, measurement of plasma concentra-
tions is most helpful for clarifi cation  [ 335 ] .
 Relapse prevention is a major goal of maintenance treatment. 
Reduction of relapse rates by TDM is highly cost-eﬀ ective, as 
relapses can lead to hospitalization  [ 377 ] . In schizophrenic 
patients, it has been shown that fl uctuations of clozapine plasma 
concentrations are predictive for relapses  [ 232 ,  670 ] and rehos-
pitalizations  [ 627 ] . In these patients, TDM may help reduce the 
risk of relapse or recurrence by increasing adherence to the 
medication. One day in the hospital is 4–16 times more expen-
sive than a single drug concentration measurement in the labo-
ratory.
 In patients exhibiting  genetic peculiarities of drug metaboliz-
ing enzymes, doses must be adapted. Kirchheiner and coworkers 
 [ 362 ,  365 ] calculated doses for PM or UM of CYP2D6 based on 
pharmacokinetic and pharmacodynamic fi ndings. However, 
even in the case of a confi rmed abnormal CYP genotype, TDM is 
recommended, because genotyping can only roughly predict to 
 Recommendation 
 Though clinical evidence is still scarce, we recommend regu-
lar monitoring of plasma concentrations under maintenance 
therapy, at least every 3–6 months, to prevent relapses and 
rehospitalizations. The frequency of TDM requests may be 
increased if patients are known to be non-adherent to the 
medication or in case of changes of co-medications or of 
smoking that aﬀ ect the pharmacokinetics of the drug. 
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which extent the plasma concentration may be changed in the 
individual patient  [ 496 ,  497 ,  625 ] .
 For  special groups of patients , such as pregnant or breastfeed-
ing patients, children or adolescent patients  [ 22 ,  373 ,  194 ] , indi-
viduals with intellectual disabilities  [ 158 ,  300 ] , or elderly 
patients, especially patients aged above 75 years  [ 374 ] , TDM is 
highly recommended.
 Any psychopharmacologic therapy of pregnant or breastfeeding 
women should assure that the plasma concentration of the drug 
is in the therapeutic reference range to minimize the risk of 
relapse on the mother’s side and, at the same time, to minimize 
risks associated with drug exposure of the fetus or the child 
 [ 169 ,  174 ] . Renal clearance and the activity of the CYP isoen-
zymes 3A4, 2D6 and 2C9, and uridine 5′-diphosphate glucuron-
osyltransferase are increased during pregnancy, whereas 
activities of CYP1A2 and 2C19 decrease  [ 21 ] . TDM in pregnant 
women and/or mothers should be carried out at least once per 
trimester and within 24 h after delivery  [ 65 ] .
 Many psychoactive drugs are not approved for use in children or 
adolescents  [ 248 ] . Pharmacokinetics and pharmacodynamics 
change during development  [ 194 ,  438 ,  514 ,  516 ] . In adolescents 
suﬀ ering from psychotic disorders, comorbid drug abuse is very 
common, and compliance with an antipsychotic treatment is 
generally marginal  [ 318 ] . Therefore, TDM is recommended in 
these patients. To raise data on the eﬀ ectiveness and tolerability 
of psychoactive drugs under every day conditions, a TDM net-
work was established for child and adolescent patients [see 
http://www.tdm-kjp.de/eng/contact.html].
 In  elderly patients , who frequently are hypersensitive to medi-
cation, TDM is helpful to distinguish between pharmacokinetic 
and pharmacodynamic factors when adverse eﬀ ects occur  [ 666 ] . 
Ageing involves progressive impairments of the functional 
reserve of multiple organs  [ 407 ] , especially renal excretion, and 
body composition changes signifi cantly  [ 361 ,  374 ] . Hepatic 
clearance can be reduced by up to 30 %. Phase I reactions are 
more likely to be impaired than phase II reactions. On the other 
hand, there are no age-dependent changes in CYP isoenzyme 
activity  [ 374 ] . Age-related changes in physiologic and pharma-
cokinetic functions as well as the comorbidity and polyphar-
macy complicate pharmacotherapy in the elderly  [ 125 ] . 
Therefore, TDM should be used for these patients to improve 
safety and tolerability of psychopharmacotherapy.
 In  individuals with intellectual disabilities , new generation 
antipsychotic drugs are frequently used. Recently published 
guidelines recommend TDM for these patients, at least when 
treated with risperidone or olanzapine  [ 158 ] . For ethical and 
legal reasons, patients with intellectual disabilities are excluded 
from clinical trials. On the other hand, many of these patients 
need medication. In these individuals, it may be diﬃ  cult to dif-
ferentiate between morbogenic and pharmacogenic reasons for 
symptom aggravation. Though evidence is poor, TDM is recom-
mended to guide the pharmacotherapy of these patients  [ 158 ] .
 In  forensic psychiatry the primary aim of pharmacotherapy, 
consisting mostly antipsychotic drugs, is reduction of dangerous 
behaviour  [ 458 ,  462 ] . To consistently reduce the risk of violence 
and aggression, adherence to the prescribed medication is 
essential  [ 658 ] . Therefore, TDM is recommended for this group 
of psychiatric patients. It is, however, not clear if eﬀ ective plasma 
concentrations are identical in forensic and general psychiatry 
patients. Castberg and Spigset  [ 113 ] analyzed data obtained by 
survey in a high security forensic unit and found higher doses in 
forensic patients than in a control group. The dose related 
plasma concentrations were signifi cantly lower for olanzapine 
but higher for quetiapine in the forensic patients than in the 
control group.
 The indication ” problem occurring after switching from an 
original preparation to a generic form (and vice versa) ” is still 
under-investigated and data are scarce  [ 124 ,  139 ] .
 Another potential indication for TDM not listed in   ●  ▶   Table 6 is 
the increasing availability of counterfeit drugs on the internet 
 [ 599 ] . WHO launched a program in 2006 to combat this illegal 
industry. There are no data published on this type of market 
concerning psychotropic drugs, but patients may be co-medi-
cated (mostly auto-medication) with other drugs obtained from 
this source. The counterfeit medications may not comply with 
purity and dosage standards and therefore increase the risk for 
interactions.
 Practical Aspects for TDM in Psychiatry
 ▼
 Essential for an eﬀ ective TDM service is the availability of appro-
priate analytical methods that produce results within a reason-
able time, i. e., 48 h, and advice from someone who understands 
pharmacokinetics and therapeutics  [ 184 ] . As shown in   ●  ▶   Fig. 1 , 
the TDM process starts with the request and ends with the fi nal 
decision about how to adjust a given patient’s therapeutic regi-
men by the health care professional.
 Request for plasma concentration quantifi cation
 As mentioned above, TDM should only be requested when there 
is evidence that the result will provide an answer to a specifi c 
question. If it is not clear what the question is, the answer is of 
little value. Typical indications are listed in   ●  ▶   Table 6 . A single 
measurement is often insuﬃ  cient for problem solving. For 
example, a series of measurements may be required at appropri-
ate intervals to clarify if a low plasma concentration is either due 
to poor compliance, reduced bioavailability or abnormally rapid 
elimination.
 Table 6  Typical indications for measuring plasma concentrations of 
 medications in psychiatry. 
 – Dose optimization after initial prescription or after dose change 
 – Drugs, for which TDM is mandatory for safety reasons (e. g., lithium) 
 –  Suspected complete or partial non-adherence (non-compliance) to 
medication 
 – Lack of clinical improvement under recommended doses 
 – Adverse eﬀ ects and clinical improvement under recommended doses 
 –  Combination treatment with a drug known for its interaction potential 
or suspected drug interaction 
 – TDM in pharmacovigilance programs 
 – Relapse prevention under maintenance treatment 
 – Recurrence under adequate doses 
 –  Presence of a genetic particularity concerning drug metabolism 
 (genetic defi ciency, gene multiplication) 
 – Pregnant or breast feeding patient 
 – Children and adolescent patient 
 – Elderly patient ( > 65 y) 
 – Individuals with intellectual disabilities 
 –  Patients with pharmacokinetically relevant comorbidities (hepatic or 
renal insuﬃ  ciency, cardiovascular disease) 
 – Forensic patient 
 –  Problems occurring after switching from an original preparation to a 
generic form (and vice versa) 
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 Fig. 1  Schematic overview of the TDM process 
as a guide for psychopharmacotherapy. Routine 
TDM is primarily applied to drugs with a narrow 
therapeutic index and a well-defi ned therapeutic 
reference range. However, TDM is useful for any 
psychotropic drug when addressing special thera-
peutic problems such as “therapy refractoriness” 
or side eﬀ ects under recommended dosage. 
Routine monitoring Specific problem
Blood sample collection, storage and shipment
Steady-state at the time of minimal drug concentration (trough level)
Dose titration
Maintenance therapy for relapse prevention 
Insufficient response, improvement and  
side effects at therapeutic doses, potential drug 
interaction or other problems
Laboratory measurement 
Use of validated method (linearity, accuracy, precision, sensitivity, specificity) 
Internal and external quality controls
Communication of results
Concentration of drug (and metabolite), unit, reference range 
Interpretation 
Clinical decision making
Further supervision of pharmacotherapy
Dose correction, continuation or change of medication  
TDM Request 
Completed request form: demographic data, diagnosis, medication, improvement, side effects
Pre -TDM: Indication for TDM? - Availability of laboratory and pharmacological advise?
 Fig. 2  Request form for therapeutic drug monitoring in psychiatry. 
LABORATORY
Address
Phone
Fax
REQUESTING HOSPITAL / DOCTOR
Address
Phone in case of alert
Fax
Drug(s) to be assayed Formulation Daily dose Date started Time of last dose 
SEVERITY OF ILLNESS 
(CGI-S)
How mentally ill is the patient 
at this time?
□ Not at all ill (1)
□ Borderline mentally ill (2)
□ Mildly ill (3)
□ Moderately ill (4)
□ Markedly ill (5)
□ Severely ill (6)
□ Extremely ill (7)
IMPROVEMENT 
(CGI-I)
Change compared to 
condition at admission?
□ Very much improved (1) 
□ Much improved (2)
□ Minimally improved (3)
□ No change (4)
□ Minimally worse (5)
□ Much worse (6)
□ Very much worse (7)
SIDE EFFECTS  (UKU)
□ not at all (0)     □ a little (1)     □ moderate (2)     □ severe (3)
□ Concentration difficulties □ Asthenia □ Sleepiness/Sedation
□ Tension/inner unrest □ Sleep disturbances □ Emotional indifference
□ Dystonia □ Rigidity □ Hypokinesia/Akinesia □ Hyperkinesia □ Tremor 
□ Akathisia □ Epilepticseizures □ Paresthesias □ Headache
□ Accomodation disturbance              □ Increased salivation     □ Dry mouth 
□ Nausea/Vomiting       □ Diarrhoea   □ Constipation    □ Micturation disturbance
□ Polyuria/Polydypsia   □ Increased sweating   □ Galactorrhoea        □  Weight gain 
□ Sexual dysfunction    □ Other (to be specified) 
Causal relationship: □ improbable    □ possible    □ probable
PATIENT DETAILS Name or Code □ Inpatient          □ Outpatient Date and time of blood withdrawal
Date of birth Sex Diagnosis / Symptom(s)
□ HIV-patient Weight (kg) Smoker    □ No        □ Moderate (<10 cig/day)           □ Heavy (>10cig/day) 
Genotype to be considered (e.g. CYP2D6, CYP2C9, CYP2C19): ___________
Other medications (include herbals, over-the-counter drugs etc)
REASON FOR REQUEST  
(tick more than one if applicable)
□ Control of adherence  
□ Dose adaptation 
□ Insufficient improvement
□ Adverse effects (specify below)
□ Drug-drug interaction
□ Control under maintenance therapy
□ Other reason (to be specified)
TDM request : Blood should be withdrawn under steady-state conditions,
preferably in the morning BEFORE taking the morning dose.
Return the completed form, together with a minimum of 2 ml serum or plasma.
Date of sample receipt: ________________
Signature:  _________________
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 TDM requests must include a completed request form (  ●  ▶   Fig. 2 ) 
which is essential for eﬀ ective drug concentration measure-
ments and an adequate interpretation of the results  [ 501 ,  635 ] . 
The form should contain the patient name or code, demographic 
data, diagnosis, medication, reason for the request, the commer-
cial and the generic name of the drug and its dose, the galenic 
formulation, the time of the last change of the dose, time of 
blood withdrawal. A brief comment on the clinical situation 
should be given for interpretation of the results. We recommend 
to use objective symptom rating, e. g., application of the clinical 
global impression (CGI) scale  [ 283 ] , to measure severity of ill-
ness and therapeutic improvement. The summary form of the 
UKU scale is useful to evaluate the occurrence and severity of 
side eﬀ ects  [ 402 ] . However, documented feedback to question-
naires indicates that clinicians often do NOT want to put that 
much information on the form. Moreover, the fi lled-in informa-
tion is often not accurate. As an alternative, feedback by phone 
may be oﬀ ered for interested physicians.
 When interpretation of the results is requested from the labora-
tory, it is absolutely necessary to fi ll out the request forms ade-
quately and completely. Thereby computerized ordering of TDM 
has advantages. It is inexpensive and it guides the ordering phy-
sician to give the relevant information required for interpreta-
tion in a comfortable way. Computerized ordering, however, is 
still not widely used. But eﬀ ective packages are on the way to 
become available (e. g., www.konbest.de).
 Blood sample collection
 Generally, TDM is carried out in plasma or serum samples. The 
analysis of whole blood, which is long established for immuno-
suppressant drugs by using immunoassays  [ 693 ] , has been 
abandoned for TDM in psychiatry. There is no consensus 
whether plasma or serum should be preferred. Defi nite experi-
mental data are still lacking which clearly demonstrate diﬀ er-
ences in the drug concentrations using either plasma or serum. 
The few available comparisons indicate that values obtained 
from serum or plasma can be used interchangeably  [ 308 ] . Most 
psychoactive drugs are intensively bound to blood cells of 
plasma proteins. Concentrations of neuropsychiatric drugs 
reported in this guideline refer to the total drug fraction in 
accordance with the literature. For imipramine, it has been 
shown that the drug is rapidly and almost totally cleared by the 
brain through a single passage in the microvasculature  [ 555 ] . 
The extraction was not signifi cantly aﬀ ected in the presence of 
albumin, lipoproteins or erythrocytes. For nortriptyline, statisti-
cal relationships between free levels of drug and clinical response 
were found to be insignifi cant  [ 506 ] . Therefore it seems likely 
that the clinical response depends on the total drug fraction. 
Analysis of psychotropic medications in other materials such as 
urine, spinal fl uid, tears, hairs or maternal milk have not been 
introduced for TDM purposes, and no validated data are availa-
ble which deal with therapeutic concentrations. Saliva oﬀ ers the 
advantage of non-invasive collection  [ 20 ,  25 ,  356 ] . However, the 
drug concentration in saliva corresponds to the free (i. e., non-
protein-bound) fraction of the drug in blood – which is for most 
psychopharmacologic medications only 10 % or less of the total 
concentration. Thus detection problems may occur when using 
saliva instead of blood plasma or serum. In any case, more data 
will have to be obtained for saliva as a matrix for measurement 
of drug concentrations.
 With few exceptions, TDM relies on trough steady-state plasma 
concentrations. Blood should therefore be collected after at least 
4 drug elimination half-lives after the start of or a change in dos-
age and during the terminal ß-elimination phase. For most psy-
chotropic drugs, elimination half-lives vary between 12 and 36 h 
(  ●  ▶   Table 5 ). Notable exceptions are quetiapine, trazodone, or 
venlafaxine, which display elimination half-lives around 6 h. 
Fluoxetine and aripiprazole have longer elimination half-lives. In 
clinical practice, the appropriate sampling time for most psy-
choactive drugs is one week after stable daily dosing and imme-
diately before ingestion of the morning dose, which usually is 
12–16 h (or 24 h if the drug is given once daily in the morning) 
after the last medication. If, for logistics reasons, blood can only 
be collected late in the morning, the patient should not be medi-
cated before blood withdrawal. In an outpatient setting it is 
important to indicate exactly the time of administration of the 
last dose for interpretation. Trough levels can then be extrapo-
lated by pharmacokinetic modelling.
 In patients treated with a depot preparation of an antipsychotic 
drug, blood should be sampled immediately before the next 
injection. Formulations of antipsychotic drugs such as haloperi-
dol decanoate or risperidone microspheres are characterised by 
a slow absorption after intramuscular administration. Maxi-
mum plasma concentration of fi rst generation depot antipsy-
chotics are reached after 1–14 days after injection, and the 
apparent elimination half-life is 2–3 weeks  [ 647 ] . Similar prop-
erties exhibits the newly introduced paliperidone palmitate 
 [ 131 ] . For risperidone microspheres the mean time to peak con-
centrations is 4 weeks and its plasma half life 4–6 days  [ 647 ] . For 
other drugs delivered in extended or retarded release formula-
tions like paliperidone  [ 70 ] or quetiapine  [ 212 ] , special atten-
tion has to be given to the time of drug intake for correct 
interpretation (see   ●  ▶   Table 5 ). In these formulations, the time of 
maximum plasma concentration is delayed but the elimination 
half-life remains essentially unchanged. The long acting olanza-
pine pamoate is a new depot formulation  [ 399 ] . The salt slowly 
releases olanzapine from the injection site into the muscle tis-
sue. However, it dissolves rapidly when it is in contact with 
blood or plasma. The latter results in high plasma concentra-
tions and may lead to marked sedation and delirium, the so 
called post-injection syndrome  [ 399 ,  647 ] . Considering this spe-
cial problem it could be useful to control plasma concentrations 
of olanzapine shortly (i. e., about 2 h) after the i. m. injection to 
monitor if plasma concentrations increase. This approach, how-
ever, relies on the rapid quantifi cation of olanzapine.
 TDM may of course be carried at any time after drug ingestion if 
unexpected side eﬀ ects are observed. It is not necessary to 
measure trough levels, but the dosing schedule should be 
reported for interpretation.
 Storage and shipment of blood samples
 When samples must be stored and sent frozen, it is required to 
prepare serum or plasma before freezing, since it is not possible 
to prepare serum or plasma from frozen blood. With few excep-
tions, serum or plasma samples can be stored in the dark 
(at 4 ℃) for at least 24 h, and most drug samples can be sent 
without freezing  [ 305 ] . Exceptions are light and/or oxygen sen-
sitive substances. For the determination of bupriopion or meth-
ylphenidate, however, serum samples must be frozen or 
extracted and stabilized immediately after blood withdrawal 
and centrifugation (see   ●  ▶   Table 5 ). Olanzapine must be stored 
frozen (̶ 20 ℃) if not analysed within 72 h  [ 305 ] . The laboratory 
should give instructions on its web site or the request form how 
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to collect (plasma volume, labelling of the samples), store and 
mail the sample.
 Laboratory measurements
 Selective and sensitive analytical methods for the quantitative 
evaluation of drugs and their metabolites (analytes) are essen-
tial for the successful conduct of TDM. Methods must be vali-
dated which includes all of the procedures that demonstrate that 
a particular method used for quantitative measurement of ana-
lytes in a given biological matrix is reliable and reproducible for 
the intended use. The fundamental parameters for this valida-
tion include (1) accuracy, (2) precision, (3) selectivity, (4) sensi-
tivity, (5) reproducibility and (6) stability. Validation involves 
documenting, through the use of specifi c laboratory investiga-
tions, that the performance characteristics of the method are 
suitable and reliable for the intended analytical applications. 
The acceptability of analytical data corresponds directly to the 
criteria used to validate the method  [ 114 ,  219 ] .
 For psychoactive drugs, chromatographic techniques (gas chro-
matography (GC), and high-performance liquid chromatography 
(HPLC), in combination with suitable detection methods, are 
preferred  [ 186 ] . They are suﬃ  ciently precise, accurate and 
robust and can be adapted to the analysis of a huge number of 
drugs. A disadvantage is the need for sample preparation before 
chromatographic separation and hence a limited sample 
throughput. Throughput can be enhanced by automated sample 
preparation prior to GC or HPLC. Some laboratories have intro-
duced HPLC with column switching which allows direct injec-
tion of plasma or serum into the HPLC system. Such procedures 
are available for a number of antidepressant  [ 269 ,  292 – 294 ,  297 , 
 298 ,  702 ,  710 ] and antipsychotic drugs  [ 368 ,  369 ,  571 – 573 ,  709 –
 712 ] . Another high-throughput chromatographic method is liq-
uid chromatography coupled with mass spectroscopy (LC-MS) 
especially tandem MS (LC-MS/MS). LC/MSMS methods can be 
applied to almost any psychotropic drug including metabolites 
 [ 577 ] . They are most sensitive and selective and can be used 
without time-consuming sample preparation. Many compounds 
can be analysed simultaneously. An excellent example is the 
LC-MS/MS method described by Kirchherr and Kühn-Felten 
 [ 366 ] . This method was validated for over 50 psychoactive drugs. 
Disadvantageous for LC-MS/MS methods are high costs. Moreo-
ver, quantifi cation can be problematic due to ion suppression 
and the availability of suitable calibration standards, preferen-
tially deuterated analogues  [ 584 ] .
 In case of suspected intoxications, TDM methods should enable 
drug analysis within 1–2 h  [ 215 ] . For this purpose automated 
methods are advantageous.
 The laboratory should not only analyse the drug but also its 
active metabolites, e. g., bupropion plus hydroxybupropion, clo-
mipramine plus desmethylclomipramine, fl uoxetine plus nor-
fl uoxetine, naltrexone plus naltrexol, risperidone plus 
9-hydroxyrisperidone or venlafaxine plus O-desmethylvenla-
faxine (  ●  ▶   Table 5 ). For some drugs, the determination of metab-
olites that do not contribute to the overall clinical eﬀ ect (e. g., 
norsertraline, normirtazapine, norcitalopram) is also useful to 
monitor drug adherence of the patient  [ 546 ] , to get information 
on his/her capacity to metabolise drugs, or to interprete drug-
drug interactions when drugs are involved exhibiting enzyme 
inhibiting or inducing properties (  ●  ▶   Table 2 ). “Normal” ratios of 
concentrations of metabolites to parent drugs that are expected 
in 68.3 % of the patients are listed in   ●  ▶   Table 3 . Any ratio outside 
the reported “normal” range should be considered as a signal 
pointing to individual abnormalities due to a drug-drug-interac-
tion, gene polymorphism, altered liver function, non-adherence 
or drug intake few hours before blood withdrawal.
 The assay of enantiomers of chiral compounds requires either 
stereoselective derivatisation of the drugs prior to their quanti-
fi cation, or their separation by chiral chromatographic GC or 
HPLC columns. LC-MS/MS may be the method of choice. As an 
example, the TDM of the enantiomers of methadone using a 
classical detection method such as fl uorescence or ultraviolet 
light absorption is often jeopardized by comedication or by 
coconsumption drugs of abuse. These problems may be circum-
vented by use of a mass detector, preferably a tandem mass spec-
trometer.
 Within the therapeutic reference range, intraday- and interday 
precision should not exceed 15 % (coeﬃ  cient of variation) and 
accuracy should not deviate more than 15 % from the nominal 
value  [ 114 ,  219 ] .
 To ensure quality and reliability of plasma concentrations assays, 
internal and external quality control procedures are mandatory. 
Samples must contain suitable internal standards, and each 
series of samples must include internal control samples. If 
standards are not available commercially, they should be pre-
pared by personnel other than those performing the assays and 
by separate weighing of reference material. Reporting of results 
requires that the results of the quality controls are within the 
expected range. If quality controls are outside the expected 
range, the reason underlying the outlier needs to be clarifi ed and 
documented.
 The laboratory has to participate in an  external quality assess-
ment scheme , although this is not a legal requirement in all 
countries. For neuropsychiatric drugs, the fi rst external quality 
program was introduced by Cardiﬀ  Bioanalytical Services Ltd in 
1972  [ 720 ] . It has currently 450 participants from 36 countries 
(www.heathcontrol.com). Instand e. V. (www.instanddev.de/
ringversuche/) is another recommended provider of external 
control, the external quality control scheme was recently 
expanded to multiple psychoactive drugs samples. Moreover, 
reference materials are also available from forensic chemistry 
(http://www.pts-gtfch.de/).
 Communication of results
 The concentration of the psychoactive drug as well as that of 
active metabolites contributing to the therapeutic action should 
be reported with reference ranges (  ●  ▶   Table 5 ) either in mass or 
molar units. We recommend the use of mass units to relate con-
centration to dose. Laboratories vary in the presentation of their 
results. The clinician should take note of the units (i. e., ng/mL, 
μg/L, μmol/L, or nmol/L) in which the results of the analysis are 
expressed. This is especially recommended for comparisons of 
TDM values obtained from diﬀ erent laboratories or with those 
in the literature. To transform molar units into mass units and 
vice versa conversion factors are given in   ●  ▶   Table 5 .
 When drug concentrations are below the limit of quantifi cation 
(LOQ), which refers to the lowest concentration of the standard 
curve that can be measured with at least 20 % accuracy and pre-
cision, this limit should be indicated.
 The results should be available for decision making within a 
clinically meaningful time. Although 24 h TDM service would be 
desirable, 48 h turnaround time is suﬃ  cient in most cases. In 
case of suspected intoxications, a few hours service is necessary 
 [ 215 ] . To assist rapid intervention in patients at risk for toxicity 
or loss of tolerability, prompt information (phone call) of the 
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treating physician is required when the laboratory measures 
drug concentrations above the “laboratory alert level” which 
was newly defi ned (see above) in the present consensus guide-
lines (  ●  ▶   Table 5 ).
 Interpretation of results
 We recommend that interpretation and pharmacologic advice 
are provided with every report. Expert interpretation of a drug 
concentration measurement and the adequate use of the infor-
mation are essential to ensure the full clinical benefi t of TDM. 
Reporting of results with inclusion of dose recommendations 
and other comments must be guided by the best available evi-
dence. Expert knowledge may be necessary to calculate dose 
corrections or to analyse drug-drug interactions. It is therefore 
advantageous for the clinician to choose a laboratory that oﬀ ers 
this service. Otherwise, the treating physician, a clinical phar-
macologist or a trained expert of the clinic has to interpret the 
results. Access to specialist advice is also necessary if TDM 
results suggest that genotyping may be advisable  [ 335 ] .
 Diagnosis and drug dose are important information for interpre-
tation, since they permit a judgement on whether a result is 
plausible or not. Moreover, it must be controlled if blood sam-
ples were collected under recommended conditions, especially 
when the plasma concentration is unexpectedly high in an out-
patient. When the drug was taken a few hours before blood sam-
pling the drug concentration can be several-fold higher than the 
trough level.
 For the interpretation of the results, it should not only be consid-
ered whether the plasma concentration of the drug is within the 
“therapeutic reference range” (  ●  ▶   Table 5 ). It must also be con-
sidered if the drug plasma concentration is consistent with the 
dose (  ●  ▶   Table 4 ). A plasma concentration may be outside the 
therapeutic reference range, just because a low or high dose was 
taken. In addition, it is wise to take into account the level of evi-
dence underlying the “therapeutic reference range” of the par-
ticular drug (  ●  ▶   Table 5 ). It should also be considered if the daily 
drug dose was given as a single or a multiple dose.
 Often it is necessary to deal with pharmacokinetic properties 
such as metabolic pathways, enzymes involved and substrate 
and inhibitor properties of all drugs taken by the patient for 
interpretation of the results. Supportive information is therefore 
given in the present updated guidelines showing literature 
based substrate (  ●  ▶   Table 1 ) and inhibitor or inducer properties 
of drugs (  ●  ▶   Table 3 ) to deal with possible drug-drug interac-
tions.
 Any drug concentration outside its dose-related reference range 
(  ●  ▶   Table 5 ) should alert the TDM laboratory to actively look for 
non-average pharmacokinetic drug disposition of the patient, 
drug-drug-interactions, gene polymorphisms that give rise to 
poor or ultra rapid metabolism, altered function of the excretion 
organs liver and kidneys, age and/or disease-related changes in 
the patient’s pharmacokinetics, compliance (adherence) prob-
lems, a non-steady state and even signal interference from other 
medications that the patient may not have declared to the pre-
scribing physician (e. g., St. John’s wort) in the laboratory analy-
sis. It may also be informative to calculate the dose related 
reference range (  ●  ▶   Table 4 ) if the drug concentration lies outside 
the recommended therapeutic reference range (  ●  ▶   Table 5 ) 
 [ 285 ] .
 Plasma concentrations must be interpreted with the clinical 
presentation in mind. Recommendations on dosage changes 
constitute the most frequent advice. Other information which 
could be of help for the physician are those related to genetic 
polymorphisms, risks of pharmacokinetic interactions in the 
case of polypragmasy, pharmacokinetic properties of the drug in 
patients belonging to a ”special population”, e. g., elderly 
patients, or patients with hepatic or renal insuﬃ  ciency. For the 
treatment of pain, relatively low plasma concentrations of tricy-
clic antidepressants may be suﬃ  cient. They may be within the 
“dose related reference range” (  ●  ▶   Table 4 ) but outside the “ther-
apeutic reference range” of   ●  ▶   Table 5 which was established for 
the indication of depression.
 A laboratory may recommend that an additional sample should 
be taken after a certain period, because in cases with unusually 
low or high plasma concentrations, repeated measurements 
may help to decide whether the patient’s adherence is incon-
stant (irregular intake of the drug) or whether the patient is an 
abnormal metabolizer.
 Since the interpretation of TDM results relies on complex quan-
titative relationships, training in clinical psychopharmacology 
and pharmacokinetics and the application of TDM is essential. 
Regular conferences with discussion of the interpretation of real 
cases are most helpful for learning. It is also recommended that 
junior psychiatrists interpret the results under supervision of an 
expert.
 Clinical decision making
 A TDM result is a guide to proper dosing of the individual patient. 
The physician has to be aware that, under optimal conditions, 
reporting of results with inclusion of dose recommendations 
and other comments by the laboratory is guided by the best 
available evidence  [ 310 ] . The laboratory, however, has only a 
restricted knowledge of the clinical situation. On the other hand, 
most treating physicians have limited pharmacokinetic know-
ledge. Therefore it is essential to be aware that optimal TDM is 
an interdisciplinary task that requires close communication 
between laboratory and clinical experts.
 If the plasma concentration of the drug is within the therapeutic 
reference range, an adaptation of the dose is, of course only rec-
ommended when clinical reasons, such as adverse eﬀ ects or 
non-response clearly justify such a decision. Evidently, the treat-
ing physician has to decide whether the treatment strategy is to 
be changed or not. On the other hand, when the advice given on 
the TDM report is not followed, the reason for this course of 
action must be substantiated to allow evaluation of the treating 
physician’s decision should the patient come to harm. Recom-
mendations for such an evaluation in a court of law have been 
recently published by the TDM-AGNP group  [ 741 ] .
 In patients with abnormally rapid elimination it may be useful 
to prescribe a dose above the maximal recommended dose, 
since such patients can exhibit drug concentrations below the 
reference range under standard doses. However, the medication 
should be changed if the patient exhibited suﬃ  ciently high drug 
concentrations for a suﬃ  ciently long treatment period, i. e., for at 
least 2 weeks, and did not improve by at least 20 %.
 When  adverse eﬀ ects are associated with clinical improvement 
under recommended doses, measurement of the plasma con-
centration may clarify if side eﬀ ects are related to exceedingly 
high drug levels in the blood. In this situation, the dose can be 
decreased, normally without risk of loss of action.
 For the treatment with antidepressant or antipsychotic drugs, 
there is good evidence that clinical non-improvement at week 2 
is highly predictive for later response and remission  [ 119 ,  138 , 
 392 ,  620 ,  621 ,  638 ] . Especially the absence of early improvement 
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appears to be a highly reliable predictor of later non-response 
 [ 358 ] . For dose titration with antidepressant and antipsychotic 
drugs we therefore recommend to include  symptom rating by 
the treating physician  [ 138 ] at baseline and at week 2 in addition 
to drug concentration measurements.   ●  ▶   Fig. 3 summarizes the 
above recommendations in a fl ow chart.
 When further plasma concentration measurements are recom-
mended after a modifi cation of the dose or after prescription of 
a comedication that is known to inhibit or enhance the metabo-
lism of the drug to be measured, the next TDM should be delayed 
until steady-state conditions are reached again. For this, the ter-
minal elimination half-life of the drug has to be considered 
(  ●  ▶   Table 5 ).
 Pharmacogenetic tests in addition to TDM
 Concentrations outside the reference range may be due to gene 
polymorphisms that give rise to slow/rapid metabolizers. As a 
consequence, the laboratory may also suggest that a pharmaco-
genetic test should be carried out  [ 14 ,  144 ,  158 ,  193 ,  335 ,  362 , 
 365 ,  377 ,  623 ,  624 ,  675 ] . Genotyping, however, is not available in 
all TDM laboratories, and we recommend consultation of 
speciali zed laboratories for interpretation of the results.
 Situations and cases where pharmacogenetic tests could advan-
tageously be combined with TDM are explained in more detail 
by Jaquenoud Sirot and coworkers  [ 335 ] . Some of the most 
important indications for the combination of genotyping with 
TDM are the following:
 ▶  the patient is treated with a substrate the metabolism of 
which shows a wide interindividual variability; 
 ▶  a drug is characterized by a small therapeutic index: risk of 
toxicity in the case of a genetically impaired metabolism, 
or on the other hand, risk of non-response due to an ultra- 
rapid metabolism and the inability to reach therapeutic 
drug  levels; 
 ▶  the patient presents unusual plasma concentrations of the 
drug or its metabolite(s) and genetic factors are suspected to 
be responsible; 
 ▶  the patient suﬀ ers from a chronic illness, which requires life-
long treatment. 
 In a patient who is genotyped as a PM or UM, the medication 
should not automatically be replaced by another as suggested by 
some authors, but the dose can often be adapted, using clinical 
judgement and TDM.
 Conclusions and Perspectives
 ▼
 The choice of pharmacologic treatment should always take into 
account the clinical presentation of the patient and consider 
psychopathology and drug history. TDM is, if used appropriately, 
a valid tool for optimising pharmacotherapy. During the past 
decades, knowledge on the metabolic fate and actions of psycho-
tropic drugs in the human body has markedly advanced. Phar-
macogenetic and environmental factors have been identifi ed 
and summarized in the fi rst part of this review. The present 
updated AGNP guidelines describe the best practice of TDM in 
psychiatry in order to promote the appropriate use of TDM.
 Although a considerable body of data for plasma concentrations 
of psychotropic drugs has been accumulated and although our 
knowledge about the quantitative relationship between plasma 
concentration and therapeutic response has improved, there is 
still a need to conduct further controlled and randomised con-
centration-response studies to improve the quality of data on 
therapeutic reference ranges. We also recommend inclusion of 
pharmacokinetic measurements during phase III and IV studies. 
Product information should be supplemented with TDM related 
data to enhance the therapeutic eﬀ ectiveness of psychoactive 
drugs. Analyses of German  [ 671 ] and French  [ 568 ] summaries of 
product characteristics (SPC) revealed that many SPC do not 
contain TDM related information in spite of available valid clini-
cal-scientifi c evidence. Another need for research is to study 
cost-eﬀ ectiveness of TDM when the method is used in an appro-
priate way. Polypharmacy is very common in psychiatry while 
essentially all TDM recommendations are based on single-med-
ication trials. Thus, the eﬃ  cacy of drug combinations constitutes 
a severely under-investigated area of TDM. Finally, one should 
never forget that TDM is an interdisciplinary task that some-
times requires the respectful discussion of apparently discrep-
ant data so that, ultimately, the patient can profi t from such a 
joint eﬀ ort.
 Fig. 3  TDM-guided dose titration of antidepres-
sant or antipsychotic drug treatment (adapted 
from  [ 311 ] ). Clinical decision making has to 
consider the clinical improvement, the duration 
of treatment, and steady-state concentration of 
the drug in plasma or serum. The steady-state is 
reached by 94 % after 4 elimination half-lives of the 
drug or active metabolites (see   ●  ▶   Table 5 ). 
Initial prescription or change of dose   
Plasma concentration
within outside
therapeutic reference range
Change of doseChange of medication
Continuation of 
medication and dose
Clinical improvement  
< 20%
Duration of treatment  
≥ 2 weeks
Blood withdrawal under steady- state
Interpretation and communication of results
Measurement of drug concentration in serum or plasma 
≥ 20%
< 2 weeks
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